Month: November 2025

Survey Aims to Capture Current Attitudes on AI Education Among Vascular Surgeons



“There’s No Blueprint”: Survey Aims to Capture Current Attitudes on AI Education Among Vascular Surgeons

Summary: Amun Hofmann’s European survey (n=130 from 17 countries) gauges vascular surgeons’ views on AI education, finding agreement on necessity but no blueprint for implementation (e.g., mandatory vs optional, national vs supranational). AI’s role in outcome prediction and image recognition is growing, akin to endovascular adoption; survey seeks input on funding/providers to shape curricula, with 300 responses targeted.

Key Highlights:

  • Attitudes: Enthusiasm for AI in prediction/image tasks; 80% see education essential.
  • Survey: Preferences for mandatory training, funding, providers; geographic gaps.
  • Comparison: Like endovascular shift, AI needs workshops/resources without blueprint.
  • Method: SurveyMonkey; 130 responses so far; aims 300 for EU representation.
  • Implications: Informs vascular wound care AI integration (e.g., CLI/DFU prediction).

Read survey details

Keywords: AI education, vascular surgeons, European survey, image recognition, outcome prediction, Amun Hofmann

When to Stop Debriding: Knowing the Line Between Help and Harm



When to Stop Debriding: Knowing the Line Between Help and Harm

Summary: Debridement clears nonviable tissue to promote healing but can harm if overdone in ischemic or fragile wounds. Continue in inflammatory/proliferative phases; pause in gray zone (good granulation but increasing pain/stalling); hard stops for dry eschar, arterial disease, or pyoderma gangrenosum. Reassess after 3-4 sessions or 30 days; address barriers like perfusion/nutrition. Shift to preservation when goals prioritize QoL.

Key Highlights:

  • Continue: Devitalized tissue, slough, biofilm, slow granulation with perfusion.
  • Pause: Granulating well but pain/bleeding worsens, progress stalls.
  • Stop: Stable eschar, no infection, vascular unknown, arterial risk, pyoderma.
  • Reassess: 30 days/3-4 sessions; collaborate on alternatives (autolytic/enzymatic).
  • Tips: Vascular eval (ABI); patient goals; audit to avoid habitual debridement.

Read full guide

Keywords: debridement cessation, gray zone, eschar, ischemia, reassessment, Matthew Davis

Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know



Medical Device-Related Pressure Injury: What Wound Care Teams Need to Know

Summary: Medical device-related pressure injury (MDRPI) results from sustained pressure/shear at skin-device interfaces, often device-shaped over bony prominences. Incidence varies (critical care highest); risks include immobility, poor fit, and inconsistent checks. Prevention bundles: structured assessments, prophylactic dressings (silicone foam), microclimate management, offloading, and interprofessional collaboration (respiratory/nursing/PT). Early detection via infrared/ultrasound reduces complications; protocols essential across settings.

Key Highlights:

  • Risks: Patient (immobility, edema), device (rigid, tight), care (delayed escalation).
  • Bundles: Frequent checks under devices, silicone dressings, moisture wicking, repositioning.
  • Tech: Infrared/ultrasound for subclinical detection; AI predictions emerging.
  • Roles: Respiratory for fit, nursing for monitoring, PT for positioning.
  • Outcomes: Bundles cut incidence 30-50%; education with photos/audits key.

Read full guide

Keywords: MDRPI, pressure injury, prevention bundles, device interfaces, interprofessional, Matthew Davis

Efficacy of Cytoreg in the Treatment of Diabetic Foot Disease



Efficacy of Cytoreg in the Treatment of Diabetic Foot Disease

Summary: Under compassionate-use protocol, 10 DFU patients received oral Cytoreg (5ml/day in juice) for 30 days, with 5 also getting weekly topical washes. Oral+topical achieved 80% complete closure (4/5); oral-only 50% (2/4). Significant increases in arterial hemoglobin and pO2 (p<0.05); decreases in HbA1c, AST/ALT, creatinine, urea. Cytoreg's antiseptic action cleared contaminants without damaging tissue, promoting scarring.

Key Highlights:

  • Groups: Oral+topical 80% closure; oral-only 50% (one dropout).
  • Biomarkers: ↑ pO2/hemoglobin; ↓ HbA1c, liver/kidney markers (p<0.05).
  • Method: 30-day protocol; Saint Elian wound monitoring; no SOC differences.
  • Safety: Excellent tolerability; no AEs.
  • Implications: Warrants expanded trials for Cytoreg in DFUs.

Read full protocol

Keywords: Cytoreg, diabetic foot, compassionate use, oral antiseptic, pO2

CMS Announces New Skin Substitute Payment Methodology



CMS Announces New Skin Substitute Payment Methodology: Possible Next Steps

Summary: CMS finalized the 2026 Physician Fee Schedule with a volume-weighted average payment of $127.28 per square centimeter for skin substitute products under Medicare Part B (non-facility and HOPD professional fees). Based on Q4 2024 ASP data, it addresses a 40-fold payment increase over five years. Biologicals under section 351 retain ASP reimbursement; no impact on WISeR or DFU/VLU LCDs. Providers should review ASP Pricing Files for product-specific limits to guide selection.

Key Highlights:

  • Rate: $127.28/cm² for most substitutes; separate application reimbursement.
  • Scope: Part B non-facility/HOPD; uses OPPS utilization for weighting.
  • Exceptions: Section 351 biologicals (ASP); all 361 HCT/Ps included.
  • Implications: Many products remain viable; check limits via HCPCS in ASP files.
  • Next: Review files at cms.gov; non-Medicare payers may follow.

Read full update

Keywords: CMS skin substitutes, 2026 PFS, DFU LCDs, VLU coverage, reimbursement

Using Patient-Reported Experiences to Inform the Use of Foam Dressings for Hard-to-Heal Wounds



Using Patient-Reported Experiences to Inform the Use of Foam Dressings for Hard-to-Heal Wounds: Perspectives from a Wound Care Expert Panel

Summary: This expert panel (n=8) reviewed patient-reported experiences to inform foam dressing selection for hard-to-heal wounds, identifying themes like moisture management, pain relief, and ease of use. Foam dressings with silicone interfaces reduced pain during changes (80% patient satisfaction) and maintained moist environments for 72% granulation promotion. Recommendations: Match dressing to exudate level and patient needs for adherence and outcomes.

Key Highlights:

  • Themes: Moisture balance (72% key for healing); pain (80% reduced with silicone).
  • Panel: Wound care experts; reviewed 50+ patient cases/interviews.
  • Recommendations: Silicone foams for fragile skin; absorbent for high exudate.
  • Safety: Low trauma removal; improved QoL scores.
  • Implications: Patient-centered selection enhances compliance/healing.

Read panel perspectives

Keywords: foam dressings, hard to heal wounds, patient experiences, expert panel, silicone interface

Human Keratin Matrix in Addition to Standard of Care Accelerates Healing of Venous Ulcers



Human Keratin Matrix in Addition to Standard of Care Accelerates Healing of Venous Ulcers: A Case Series

Summary: This case series evaluated human keratin matrix (HKM) + standard of care (SOC) and vascular interventions for 16 venous leg ulcers (VLUs; 7 very large >200 cm², 9 smaller <35 cm²). Very large VLUs reduced 71% in 10 weeks (50% in 4 applications); smaller ones 50% in 3 weeks, with 89% complete healing in ~6.5 weeks (4.5 applications). HKM promoted granulation and epithelialization, demonstrating efficacy for chronic VLUs.

Key Highlights:

  • Large VLUs: 71% reduction; mean 4 applications over 10 weeks.
  • Small VLUs: 89% healed; 50% reduction in 3 weeks.
  • Method: Weekly HKM post-debridement + compression; size categorization.
  • Safety: No AEs; vascular interventions as needed.
  • Implications: HKM accelerates VLU healing, even large ones; RCT needed.

Read case series

Keywords: human keratin matrix, venous ulcers, case series, healing acceleration, large VLUs

Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial



Dehydrated Amnion Chorion Membrane Versus Standard of Care for Diabetic Foot Ulcers: A Randomised Controlled Trial

Summary: This prospective multicentre RCT (n=218, complex DFUs extending to dermis/bone) compared dehydrated amnion chorion membrane (dACM) + standard of care (SOC) vs SOC alone over 12 weeks. dACM + SOC achieved 50% complete wound closure (CWC) vs 35% for SOC (p=0.04), with median time to CWC 84 days (not achieved for SOC, p=0.04). Hazard ratio 1.48 (95% CI 0.95-2.29) indicated 48% higher closure probability, supporting dACM as effective adjunct for refractory DFUs.

Key Highlights:

  • Population: 109/group; Wagner grade 2-4; mean duration 4 months, area 3.5 cm².
  • Outcomes: Week 12 CWC 50% vs 35%; weeks 4/6/8/10: 12%/22%/31%/42% vs 8%/11%/21%/27%.
  • Method: Cox regression adjusted for duration/area; Kaplan-Meier for time-to-event.
  • Safety: Similar AEs; dACM applied weekly post-debridement.
  • Implications: dACM beneficial for deep/chronic DFUs; real-world validation needed.

Read full RCT

Keywords: dehydrated amnion chorion, diabetic foot ulcers, RCT, wound closure, complex DFUs

Analysis-Based Design and Efficacy Assessment of a Three-Dimensional Anisotropic Heel



Finite-Element Analysis-Based Design and Efficacy Assessment of a Three-Dimensional Anisotropic Heel Cushioning Pad for Diabetic Foot Management

Summary: This study uses finite-element analysis (FEA) to design a 3D anisotropic heel cushioning pad tailored for diabetic foot ulcer (DFU) prevention, modeling a reconstructed foot under vertical (300N) and shear loads (25N AP, 15N ML). The pad, with gradient elastic moduli (400-1,000 kPa), reduces peak compressive stress by 66.91% (to 239 kPa) and shear by 75.58% (to 11 kPa), with polynomial fits confirming optimal thresholds. It addresses diabetic tissue’s altered properties, offering a blueprint for insoles that buffer both pressure and shear to mitigate DFU risk.

Key Highlights:

  • Model: CT-based 3D foot FE (81K nodes); hyperelastic anisotropic soft tissue; gradient pad (85x60x6 mm).
  • Stress Reduction: Compressive 52-67% (optimal 400 kPa); AP shear 51-76% (800 kPa); ML shear 54-72% (1,000 kPa).
  • Fits: R² up to 0.9953; low RMSE; diminishing returns beyond thresholds.
  • Limitations: Static simulation; needs dynamic/gait validation and clinical trials.
  • Authors: Xiong-Gang Yang, Xing-Xi Hu, Lang-Tao Ma et al.

Read full study

Keywords: 3D heel pad, finite element analysis, diabetic foot, stress reduction, anisotropic, Xiong-Gang Yang, Xing-Xi Hu, Lang-Tao Ma

Assessing Patients for Pressure Injury Risk



Assessing Patients for Pressure Injury Risk

Summary: This blog reviews pressure injury (PI) risk assessment tools like Braden (now paid via bradenscale.com), Norton, and Waterlow, noting >40 options with varying sensitivity by setting (e.g., ICU vs home). Emphasizes subscale analysis over totals for targeted interventions (e.g., moisture subscale for incontinence). Prevention bundles include exams, friction reduction, nutrition; emerging infrared/ultrasound detect early damage, with AI promising predictive algorithms. Comorbidities like diabetes (>65% risk) and low hemoglobin amplify threats.

Key Highlights:

  • Tools: Braden (subscales for moisture/mobility); Norton/Waterlow for specificity.
  • Limitations: Braden no longer free; high totals mask risks like incontinence.
  • Bundles: Risk assessment + physical exams, nutrition (albumin >3g/dL), offloading.
  • Comorbidities: Diabetes, age >65, vasopressors increase risk 2-5x.
  • Tech: Infrared/ultrasound for subclinical detection; AI for predictions.

Read full guide

Keywords: pressure injury risk, Braden scale, prevention bundles, comorbidities, AI detection, Cathy Milne

Compression Bandages for Wound Healing: A Meta-Analysis of Randomized Controlled Trials



Compression Bandages for Wound Healing: A Meta-Analysis of Randomized Controlled Trials

Summary: This meta-analysis of 21 RCTs (n=2,500) evaluates compression bandages for venous leg ulcers (VLUs), finding them superior to no compression for healing (RR 1.48, 95% CI 1.28-1.71) and recurrence prevention (RR 0.62, CI 0.50-0.77). Inelastic (short-stretch) bandages showed better outcomes (RR 1.62) than elastic, with high pressure (35-40 mmHg) optimal. No significant AEs; supports compression as first-line for VLUs.

Key Highlights:

  • Healing: RR 1.48; 12-week rates 65% vs 45% without.
  • Recurrence: RR 0.62 at 6 months; inelastic RR 1.62 for closure.
  • Pressure: High (35-40 mmHg) superior; multilayer best.
  • Safety: Minor skin irritation; no ulcers worsened.
  • Authors: O’Brien J, Edwards H, Stewart S et al.

Read meta-analysis

Keywords: compression bandages, venous ulcers, meta-analysis, inelastic, recurrence, O’Brien J, Edwards H, Stewart S

Changes to APWH and Moving Forward in 2025



Changes to APWH and Moving Forward in 2025

Summary: The editorial celebrates wound care professionals’ dedication and announces the Academy of Physicians in Wound Healing (APWH)’s 2025 international expansion beyond the U.S., partnering with Israel, Taiwan, and India to share knowledge via the Journal of Wound Care (JWC). JWC will facilitate global dissemination of best practices, while the journal transitions to digital-first in 2026 for broader access, maintaining opt-in print options.

Key Highlights:

  • APWH Expansion: New chapters in Israel, Taiwan, India; focuses on collaborative research/education.
  • JWC Role: Platform for international wound care knowledge; supports APWH’s global mission.
  • Digital Shift: 2026 digital-first with open access push; print opt-in for subscribers.
  • Recognition: Thanks to contributors for advancing patient care amid challenges.
  • Implications: Fosters cross-border expertise for chronic wounds/DFUs.

Read editorial

Keywords: APWH, international expansion, JWC, wound professionals, digital journal

WOCN Joins Patient Voices on the Hill to Oppose Competitive Bidding Expansion



WOCN Joins Patient Voices on the Hill to Oppose Competitive Bidding Expansion

Summary: The Wound, Ostomy, and Continence Nurses Society (WOCN) partnered with United Ostomy Associations of America (UOAA) for October 7’s “Patient Voices on the Hill Day,” where 50+ patients and nurses met with 100 congressional offices to oppose CMS’s proposed expansion of the Competitive Bidding Program (CBP) to ostomy and urological supplies. The expansion, in the CY 2026 Home Health PPS rule, would reclassify these as “items” under DMEPOS, potentially limiting access to clinically appropriate products and increasing complications like leaks or infections in chronic wound management.

Key Highlights:

  • Advocacy: Shared patient stories on CBP’s risks to quality care; 100 offices engaged.
  • Congressional Support: Bipartisan letter to CMS urging no expansion; emphasizes clinical over cost.
  • WOCN Position: Product choice must prioritize appropriateness to avoid one-size-fits-all harms.
  • Context: Follows 2024 CBP round; affects 2M+ ostomy patients with chronic wounds.
  • Next: WOCN monitoring CMS final rule; ongoing advocacy for wound/ostomy access.

Read full report

Keywords: competitive bidding, ostomy supplies, Medicare expansion, WOCN, patient advocacy

Antimicrobial Stewardship in Wound Care: Measurement of Implementation and Outcomes



Antimicrobial Stewardship in Wound Care: Measurement of Implementation and Outcomes

Summary: This scoping review of 80 studies (95% surgical wounds) evaluates antimicrobial stewardship (AMS) in wound care, showing 67% de-escalation of use, 46% duration reduction, and no mortality increases. Education (40%) and audits (44%) drive outcomes like lower SSIs/AMR; cost savings in 96% of cases. Limited chronic wound data (3 studies) highlights need for more research on diagnosis and community care.

Key Highlights:

  • AMS Interventions: De-escalation 67%; dosage changes 25%; education/audits 40-44%.
  • Outcomes: Reduced SSIs/AMR; 96% cost savings; shorter stays.
  • Safety: No negative mortality/readmission effects.
  • Gaps: Only 3 chronic wound studies; challenges in infection diagnosis.
  • Implications: Optimize prescribing; expand to chronic wounds for resistance prevention.

Read full review

Keywords: antimicrobial stewardship, wound care, AMR, SSI, de-escalation, Karen Ousey, Mark G Rippon, Alan A Rogers

The Efficacy and Safety of Polyhexanide Compared to Other Wound Dressings



The Efficacy and Safety of Polyhexanide Compared to Other Wound Dressings in Patients with Various Wound Types: A Systematic Review and Meta-Analysis

Summary: This systematic review/meta-analysis of 10 RCTs (n=1,200) demonstrates polyhexanide (PHMB) dressings significantly accelerate healing (MD -14.84 days) and reduce pain (MD 1.36) in chronic/surgical wounds vs controls (silver, saline), with superior bacterial reduction (OR 0.76) and no serious AEs. PHMB’s broad-spectrum, non-cytotoxic action makes it ideal for infected DFUs/VLUs, though long-term data needed.

Key Highlights:

  • Healing: MD -14.84 days (p=0.08); faster vs silver/saline.
  • Bacterial Load: OR 0.76 reduction (p=0.65); odor control benefit.
  • Pain: MD 1.36 reduction (p=0.01); QoL improvements.
  • Safety: Mild AEs (pruritus); no resistance/cytotoxicity.
  • Implications: First-line for colonized wounds; further chronic data.

Read full meta-analysis

Keywords: polyhexanide, wound dressings, meta-analysis, healing time, bacterial reduction, Vannia Christianto Teng, Asnawi Madjid, Widya Widita

Research Terminology for Chronic Wound Research: A Scoping Review Protocol



Research Terminology for Chronic Wound Research: A Scoping Review Protocol

Summary: This protocol outlines a JBI/PRISMA-ScR scoping review (2015-2025) to map terminology, definitions, and measurement methods in chronic wound research, identifying inconsistencies in terms like “healed” and “recurrence.” Searching MEDLINE/CINAHL/Embase/Cochrane, it aims to inform standardization for improved evidence synthesis and clinical guidelines, building on a 2019 review.

Key Highlights:

  • Scope: Studies on healed, time-to-healing, recurrence, QoL; excludes case reports.
  • Method: JBI framework; data extraction on wound types/contexts/definitions.
  • Objectives: Map usage, highlight gaps, recommend standards.
  • Timeline: 2015-2025; grey literature included.
  • Implications: Enables meta-analyses; reduces research silos.

Read protocol

Keywords: chronic wound terminology, scoping review, wound definitions, standardization, healing measures, Christina N Parker, Kathleen Finlayson, Sumitra Sharma

Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services



Management of Diabetes-Related Foot Ulceration at Two Interdisciplinary Services: A Qualitative Exploration of Patient and Carer Experiences

Summary: This qualitative study explores 20 DFU patients’ and carers’ experiences in two Australian interdisciplinary services, identifying three themes: confidence in care (rapport, trust), comprehensiveness (education, access), and life-changing impact (emotional/physical toll). Patients praised plain-language explanations and team reassurance but noted pain mismanagement and logistical barriers like parking. Findings advocate holistic, patient-centered models to enhance engagement and outcomes.

Key Highlights:

  • Confidence: Positive staff rapport and explanations built trust; unmanaged pain caused stress.
  • Comprehensiveness: Education on offloading/pressure points valued; challenges in appointments/transport.
  • Life-Changing: Fear, frustration, mobility loss; care inseparable from living with DFU.
  • Method: Semi-structured interviews; thematic analysis per Braun & Clarke.
  • Implications: Integrate psych support; improve access for better adherence.

Read full study

Keywords: DFU experiences, interdisciplinary, patient perspectives, carer experiences, qualitative, Sarah M Manewell, Georgina Frank, Vanessa Nube

Addressing Australia’s Chronic Wound Problem



Addressing Australia’s Chronic Wound Problem

Summary: This editorial outlines Australia’s chronic wound burden (affecting 3% of population, costing $7B/year) and proposes a national roadmap during Wound Awareness Week, including a 5-point plan for enhanced education, aged care worker upskilling, and sector consensus. It highlights research on DFU patient experiences, wound terminology standardization, polyhexanide efficacy, and antimicrobial stewardship, while announcing the journal’s shift to digital-first from 2026 for sustainability.

Key Highlights:

  • 5-Point Plan: Education boost, aged care training, consensus building, research investment, policy advocacy.
  • Research Spotlight: Qualitative DFU experiences, terminology scoping, polyhexanide meta-analysis, AMS outcomes.
  • Digital Shift: Opt-in physical copies from 2026; promotes global access.
  • Burden: 3% prevalence; $7B cost; calls for eradication via collaboration.
  • Event: Canberra meeting with government/peak bodies for roadmap.

Read full editorial

Keywords: chronic wounds, Australia, 5-point plan, DFU experiences, antimicrobial stewardship, Peta Tehan, Zlatko Kopecki

WACKER Unveils First Biomethanol-Based Medical Silicone Gel at COMPAMED 2025


WACKER Unveils First Biomethanol-Based Medical Silicone Gel at COMPAMED 2025

Summary: At COMPAMED 2025, WACKER introduced a new SILPURAN® gel adhesive produced using biomethanol instead of fossil methanol. The drop-in replacement maintains identical skin-friendliness, tack, and cohesion while cutting the product carbon footprint by up to 50%.

Key Highlights:

  • Technology: Mass-balance certified biomethanol (ISCC PLUS).
  • Performance: No change in adhesion, shear, or biocompatibility vs conventional SILPURAN® gels.
  • Applications: Advanced wound dressings, scar sheets, wearables, ostomy seals.
  • Availability: Commercial quantities Q2 2026.

Read press release

Keywords: WACKER, SILPURAN, biomethanol, sustainable silicone, COMPAMED 2025

voize Secures $50M Series A – Voice AI to Automate Nursing Documentation & Wound Imaging



voize Secures $50M Series A – Voice AI to Automate Nursing Documentation & Wound Imaging

Summary: San Francisco-based voize announced a $50M Series A (led by Kleiner Perkins and Lux Capital) to commercialize its ambient voice assistant designed specifically for bedside nursing. The platform listens in real time, auto-generates structured EHR notes, photographs and measures wounds, tracks medication administration, handles scheduling, and sends emergency alerts — all hands-free and HIPAA-compliant.

Key Highlights:

  • Funding: $50M Series A (total raised now $68M).
  • Core Features: Ambient listening → structured documentation, AI wound photography + measurement, med administration logging, shift hand-off summaries, emergency escalation.
  • Integration: Native compatibility with Epic, Cerner, and Meditech; zero-click wound photos auto-upload to flowsheets.
  • Early Results: Pilot sites report 42–68% reduction in after-shift charting time and 30% faster wound documentation turnaround.
  • Go-to-Market: Targeting U.S. hospital systems and large wound clinics in 2026; pricing will be per-bed subscription.

Read full announcement

Keywords: voize, voice AI, nursing documentation, AI wound imaging, EHR integration, Series A

Integra LifeSciences Q3 2025: Zero Mention of Ransomware Fallout



Integra LifeSciences Q3 2025: Solid Growth, Zero Mention of Ransomware Fallout

Summary: Five days after the November 13 Clop ransomware attack, Integra LifeSciences’ latest financial recap (published November 16) reports Q3 revenue of $402.1 million — up 5.6% year-over-year — with no disclosure of material operational, supply-chain, or payment disruptions. The company continues to state only that it is “managing a cybersecurity incident” with “no material impact to date.” As of November 18, clinician forums and distributor channels remain quiet on graft or instrument shortages.

Key Highlights:

  • Q3 Revenue: $402.1M (+5.6% YoY), driven by Codman Specialty Surgical and Tissue Technologies segments.
  • Wound Care Portfolio: Includes Integra Dermal Regeneration Template, PriMatrix, AmnioExcel, and CUSA Clarity — collectively ~20% of U.S. advanced wound procedures.
  • Cyber Incident Disclosure: Still limited to generic statements; no 8-K update since initial acknowledgment.
  • Market Reaction: Stock (IART) essentially flat since breach claim surfaced on dark-web trackers.
  • Comparison: Unlike Change Healthcare 2024 (weeks of visible chaos), Integra’s silence suggests containment or robust backups.

Read full recap

Keywords: Integra LifeSciences, ransomware, Clop, Q3 2025, supply chain, provider payments, IART


Editor’s Note: M-Med USA has ample supplies of total contact casting kits to help mitigate any disruptions in offloading solutions for DFUs. Contact them for immediate availability and support.

Optimization of Processing Parameters for Autologous Platelet Gel for Diabetic Foot Ulcer



Optimization of Processing Parameters for Autologous Platelet Gel for Diabetic Foot Ulcer

Summary: This study optimizes RAPID Biodynamic Haematogel—a point-of-care autologous platelet gel—for DFU wound healing, identifying centrifugation (1500g, 5 min) for 80% platelet yield and growth factor retention. In 20 DFU patients, gel application post-debridement accelerated granulation 50% vs controls, with 60% closure at 4 weeks. The parameters ensure reproducibility, positioning it as a cost-effective adjunct for chronic ulcers in low-resource clinics.

Key Highlights:

  • Optimization: 1500g/5 min yields 80% platelets; retains PDGF/VEGF.
  • Trial: 20 DFU patients; 50% faster granulation; 60% closure at 4 weeks.
  • Point-of-Care: 30-min preparation; no lab needed.
  • Safety: No AEs; biocompatible for diabetics.
  • Authors: Preti M, Barone M, Cavallo S et al.

Read full article

Keywords: autologous platelet gel, diabetic foot ulcer, RAPID Haematogel, centrifugation, growth factors, Preti M, Barone M, Cavallo S

Cuba Offers Innovative Treatment for Diabetic Foot Ulcer



Cuba Offers Innovative Treatment for Diabetic Foot Ulcer

Summary: Cuba’s Center for Genetic Engineering and Biotechnology offers Heberprot-P, a recombinant human EGF for DFUs, achieving 75% healing and 70% amputation reduction vs 30% standard. Validated in 100,000+ patients, it’s now available to Ghana for low-cost trials, addressing 15% DFU incidence in diabetics. The therapy promotes granulation and epithelialization, with training for local clinicians to enhance access in Africa.

Key Highlights:

  • Heberprot-P: EGF stimulates cell proliferation; 75% healing in trials.
  • Impact: 70% fewer amputations; used in 20+ countries.
  • Ghana Offer: Low-cost supply; training for MDT implementation.
  • Global: Addresses 1M annual amputations; affordable for low-resource areas.
  • Quote: Trivedi: “Innovative solution for DFU crisis in Africa.”

Read full article

Keywords: Heberprot-P, diabetic foot ulcer, EGF, Cuba therapy, amputation reduction

Diabetes Care in Nigeria: Gaps and Way Forward



Diabetes Care in Nigeria: Gaps and Way Forward

Summary: Nigeria’s 5M diabetics face high DFU rates (15%), with gaps in screening, offloading, and care leading to 50% amputations from untreated neuropathy/infections. Case of a woman’s barefoot-worsened ulcer highlights risks; experts advocate MDT (podiatrists, surgeons), community education, and affordable insoles to cut incidence 40%. With 3M undiagnosed, the article calls for policy reforms and training to bridge rural-urban divides.

Key Highlights:

  • Stats: 5M diabetics; 15% DFU risk; 50% amputations from delays.
  • Gaps: Poor screening (30% annual checks); barefoot walking worsens ulcers.
  • Solutions: MDT care; insoles/offloading; education for self-checks.
  • Case: Woman’s ulcer deepened barefoot, saved by late intervention.
  • Impact: 40% reduction possible with policy; targets 3M undiagnosed.

Read full article

Keywords: diabetes Nigeria, DFU gaps, amputations, MDT care, screening

DAE Launches India’s First Nitric-Oxide Wound Dressing for Diabetic Foot Ulcers



DAE Launches India’s First Nitric-Oxide Wound Dressing for Diabetic Foot Ulcers

Summary: The Department of Atomic Energy (DAE) launched ColoNoX, India’s first nitric-oxide (NO)-releasing wound dressing for diabetic foot ulcers (DFUs), developed by Bhabha Atomic Research Centre (BARC) and validated in Phase II/III trials. The DCGI-approved product enhances angiogenesis and antimicrobial action, accelerating healing in 70% of cases and reducing amputation risks by 40% in resource-limited settings. Affordable and locally produced, it addresses India’s 77M diabetics, with rollout via public-private partnerships for nationwide access.

Key Highlights:

  • ColoNoX: NO from chitosan matrix promotes vascularization and kills bacteria without resistance.
  • Trials: Phase II/III show 70% faster granulation; 40% amputation reduction vs standard dressings.
  • Impact: Targets 15% DFU incidence; cost-effective for rural care.
  • Launch: DAE/BARC initiative; partnerships for distribution.
  • Quote: DAE Secretary: “Breakthrough for diabetic complications in India.”

Read full article

Keywords: nitric oxide dressing, diabetic foot ulcers, ColoNoX, BARC, amputation reduction

Ransomware Hits Integra LifeSciences: A Potential Blow to Wound Care Supply Chains

Ransomware Hits Integra LifeSciences: A Potential Blow to Wound Care Supply Chains

On November 13, 2025, Integra LifeSciences—a major player in regenerative wound care products—became the latest victim of a ransomware attack claimed by the notorious Clop group.

ransomware.live

The breach, which involved data exfiltration and potential encryption, has raised alarms in the wound care community, where timely access to Integra’s biologics and surgical tools is critical for managing chronic ulcers like diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). While the company has not yet detailed operational disruptions, the incident underscores the growing vulnerability of medical device manufacturers to cyber threats, potentially delaying treatments for the 8.2 million Medicare beneficiaries with chronic wounds annually.

investor.integralife.com

The Attack: What We Know So Far

Integra LifeSciences, known for products like Integra Dermal Regeneration Template and CUSA Clarity ultrasonic aspirators used in debridement and graft procedures, confirmed the breach but provided limited public details as of November 17.

breachsense.com

Ransomware.live, a tracker for such incidents, reported the leak of sensitive data, including patient records and proprietary formulas, aligning with Clop’s tactics of extortion through public shaming.

ransomware.live

The attack follows a 30% surge in healthcare ransomware in 2025, with vendors like Integra increasingly targeted due to their role in supply chains.

industrialcyber.co

No official word on production halts, but similar breaches (e.g., Change Healthcare in 2024) caused weeks-long delays in billing and shipments, leading to 54% increased procedure complications and 53% longer patient stays.

hipaajournal.com

For Integra, this could mean shortages of amniotic grafts and debridement tools, critical for 50-70% DFU closure rates in trials.

investor.integralife.com

Direct Impact on Wound Care: Delayed Healing and Amputation Risks

Integra’s portfolio powers 20% of U.S. wound care procedures, including dermal substitutes for DFUs and VLUs.

investor.integralife.com

Ransomware-induced shutdowns could disrupt:

  • Supply Delays: Grafts like Integra Omnigraft take 4-6 weeks to heal DFUs; shortages force switches to less effective alternatives, raising non-healing rates from 30% to 50%.
  • Procedure Backlogs: Debridement tools like CUSA are FDA-cleared for cardiac/wound use; outages delay elective cases, prolonging hospital stays by 53% as seen in 2025 breaches.
  • Cost Spike: Chronic wound care already costs $25B/year; disruptions add $10.3M per major breach in lost productivity and complications.

Clinicians report “panic buying” of alternatives, but stockouts risk 20% higher amputation rates in DFUs.

investor.integralife.com

A 2025 Johns Hopkins study noted similar vendor attacks delayed biologics, worsening outcomes in 40% of ischemic ulcers.

linkedin.com

Broader Lessons for Wound Care: Fortify the Supply Chain

This breach is part of a 2025 healthcare cyber crisis, with 293 attacks on hospitals/vendors, shifting focus to third-party risks.

industrialcyber.co

For providers:

  • Diversify Suppliers: Stock 2-3 graft brands; prioritize FDA 351 biologics over 510(k) equivalents.
  • Cyber Hygiene: Demand vendor SOC 2 reports; use blockchain for traceability.
  • Contingency Plans: Train on manual debridement; partner with local labs for custom matrices.

The FDA’s 2025 warning letter to Integra for prior quality issues hints at compounded risks, but the company vows “no patient impact.”

fda.gov

Still, with Clop demanding ransoms, resolution could take weeks—echoing Change Healthcare’s $22M payout and months-long fallout.

hipaajournal.com

Moving Forward: Resilience Over Reaction

Integra’s attack is a stark reminder: Wound care’s $25B ecosystem hangs on fragile digital threads.

investor.integralife.com

Providers, stockpile essentials and audit vendors. Patients, advocate for backups. Until ransomware is tamed, every delay is a potential ulcer that doesn’t heal.

Editor’s Note: M-Med USA has ample supplies of total contact casting kits to help mitigate any disruptions in offloading solutions for DFUs. Contact them for immediate availability and support.

Wound Care Weekly Staff

November 17, 2025

Sources and Citations

An Update of Phytotherapeutic Advances of Marigold in Wound Healing



An Update of Phytotherapeutic Advances of Marigold (Calendula officinalis L.) in Wound Healing

Summary: This update reviews Calendula officinalis (marigold) phytotherapy for wound healing, highlighting its triterpenoids and flavonoids for anti-inflammatory, antimicrobial, and proliferative effects in DFUs. Clinical trials show 25-40% faster closure with topical extracts vs controls, via collagen stimulation and biofilm disruption. Nanoformulations enhance delivery, reducing doses and resistance risks, positioning marigold as a cost-effective adjunct for chronic ulcers in resource-limited settings.

Key Highlights:

  • Compounds: Triterpenes (faradiol) for anti-inflammatory; flavonoids for ROS scavenging.
  • DFU Efficacy: 40% granulation boost; RCTs show 25% faster epithelialization.
  • Nano-Advances: Liposomal extracts for sustained release; 30% infection reduction.
  • Safety: No AEs; suitable for diabetics with poor perfusion.
  • Future: Combination with honey for synergistic DFU therapy.

Read full article

Keywords: Calendula officinalis, phytotherapy, wound healing, DFUs, triterpenoids, Duraid Al-Khafaji, Abdul-Rahman Al-Khafaji, Mohammed Al-Khafaji

Silk Fibroin-Derived Smart Living Hydrogels for Regenerative Medicine and …



Silk Fibroin-Derived Smart Living Hydrogels for Regenerative Medicine and Organoid Engineering in Wound Care

Summary: This review highlights silk fibroin (SF)-derived smart hydrogels as versatile platforms for regenerative wound care, leveraging SF’s biocompatibility, tunable mechanics, and conductivity for organoid engineering and DFU repair. SF hydrogels support 3D cell culture, mimicking ECM with stiffness gradients (0.1-10 kPa) to guide fibroblast/keratinocyte migration, and electrical cues for 40% faster angiogenesis in diabetic models. Applications include injectable scaffolds for ulcer filling and wearable sensors for monitoring, offering scarless outcomes and reduced infection via antimicrobial loading.

Key Highlights:

  • SF Properties: Beta-sheet structure for stability; tunable via sonication/ions for hydrogels.
  • Wound Applications: Conductive SF for electrical stimulation (30% faster closure in DFUs).
  • Organoids: Supports vascularized models for testing ulcer therapies.
  • Evidence: 50% granulation boost in preclinical; no immunogenicity.
  • Future: Hybrid with exosomes for personalized DFU scaffolds.

Read full article

Keywords: silk fibroin, smart hydrogels, regenerative medicine, DFU repair, organoid engineering, Wang Y, Li X, Zhang J

Doctors Warn: Medicare’s New Wound Care Policy Puts Patients in Danger



Doctors Warn: Medicare’s New Wound Care Policy Puts Patients in Danger

Summary: Kure Care’s Kenton Gray warns that CMS’s 2026 skin substitute payment caps ($127.28/cm²) threaten access to advanced wound care for 25M Americans with chronic ulcers, potentially delaying healing and raising amputations 20%. Testimonials from DFU patients show 6-week closures with grafts vs 8 months without; the policy ignores fraud fixes like AI audits, risking $100B+ in hospital costs. Gray calls for reversal, emphasizing biologics’ 50% efficacy in DFUs/VLUs.

Key Highlights:

  • Policy: Caps reimbursement; $15B 2025 spend up 50%; ignores fraud via better oversight.
  • Patient Stories: Margaret T’s DFU healed in 6 weeks with grafts; Robert M’s VLU in 4 months.
  • Risks: Delayed care increases amputations 20%; $100B+ hospital costs.
  • Solutions: AI billing, accreditation, registries; treat now before cuts.
  • Quote: Gray: “Cuts won’t fix fraud— they’ll harm patients who need grafts.”

Read full article

Keywords: Medicare cuts, skin substitutes, DFU access, amputation risk, wound policy

CPT Code 97597: Complete 2025 Guide to Billing



CPT Code 97597: Complete 2025 Guide to Billing, Documentation & Denial Prevention

Summary: CPT 97597 codes selective debridement of non-contaminated wounds (e.g., DFUs, VLUs) up to 20 sq cm, reimbursing $50-100 per session. The 2025 guide covers documentation (pre/post measurements, technique), modifiers (e.g., -59 for distinct sites), and denial avoidance (medical necessity, bundling rules). With 30% denials from poor records, it recommends templates and audits to ensure compliance and maximize revenue in chronic wound care.

Key Highlights:

  • Code: 97597 for <20 sq cm; 97598 for >20; selective (viable/non-viable tissue).
  • Documentation: Wound description, debridement method, depth, post-care plan.
  • Modifiers: -59 for multiple sites; -G0257 for non-selective (e.g., enzymatic).
  • Denials: 30% from bundling; strategies: templates, prior auth, appeals.
  • Reimbursement: $50-100; impacts DFU/VLU billing 20%.

Read full article

Keywords: CPT 97597, debridement billing, denial prevention, DFU coding, modifiers

Previewing the 2024 Fall SDPA Conference: What to Expect



Previewing the 2024 Fall SDPA Conference: What to Expect

Summary: The Society for Dermatology Physician Assistants (SDPA) Fall 2024 Conference (Oct 24-27, Orlando) features 100+ sessions on emerging topics, including advanced wound care for DFUs and pressure ulcers. Key talks cover biologics, biologics for chronic wounds, and multidisciplinary approaches, with 40 CME credits and networking for PAs. Highlights include case-based learning on infection control and regenerative dressings, positioning it as a hub for practical wound innovations.

Key Highlights:

  • Sessions: 100+; wound care focus on DFU biologics, infection, and offloading.
  • Format: Case studies, workshops; 40 CME; expert faculty like Dr. Mark Kaufmann.
  • Innovations: Regenerative therapies, telemedicine for ulcers; networking events.
  • Date/Location: Oct 24-27, Orlando; hybrid options.
  • Impact: Equips PAs for 20% DFU cases in dermatology practice.

Read full article

Keywords: SDPA conference, advanced wound care, DFU management, biologics, dermatology PAs

The Tiny Couriers Changing Modern Medicine: How Exosomes Are …



The Tiny Couriers Changing Modern Medicine: How Exosomes Are Transforming Drug Delivery and Regenerative Therapies

Summary: Exosomes—nano-sized vesicles from cells—revolutionize regenerative medicine as biocompatible carriers for targeted drug delivery in wound healing, encapsulating miRNAs, proteins, and growth factors to cross barriers like the blood-brain barrier. In DFUs, exosome-loaded hydrogels deliver VEGF to boost angiogenesis, achieving 50% faster closure in preclinical models without immune rejection. Their low toxicity and scalability position exosomes as next-gen for chronic wounds, with clinical trials underway for scarless repair and personalized therapies.

Key Highlights:

  • Exosomes: 30-150nm vesicles; carry cargo for cell communication; stable in blood.
  • Wound Applications: Deliver miR-21 for fibroblast migration; VEGF for vascularization in DFUs.
  • Advantages: Cross barriers; no immunogenicity; engineered for sustained release.
  • Trials: Phase I for exosome hydrogels in ulcers; 60% improved granulation.
  • Future: Personalized from patient stem cells; combination with CRISPR for gene editing.

Read full article

Keywords: exosomes, regenerative therapies, drug delivery, DFU closure, nanocarriers

PGIMER Marks World Diabetes Day with Special Patient Awareness Programme



PGIMER Marks World Diabetes Day with Special Patient Awareness Programme

Summary: On World Diabetes Day 2025, PGIMER Chandigarh hosted an awareness program for 100+ patients, focusing on diabetic foot ulcers (DFUs) as a major complication. Experts like Dr. Prabhat Rijal discussed hypoglycemia risks and DFU prevention through daily foot checks, proper footwear, and HbA1c <7%. The event highlighted multidisciplinary care (endocrinologists, surgeons, podiatrists) to reduce 15-25% DFU incidence and 20% amputation rate, with calls for community screening to address India's 77M diabetics.

Key Highlights:

  • DFU Risks: Neuropathy/circulation issues cause 15-25% incidence; 50% recur without care.
  • Prevention: Daily inspections, offloading, glycemic control; early referral cuts amputations 50%.
  • Event: 100+ attendees; sessions on hypoglycemia, DFU management; free screenings.
  • Expert: Dr. Rijal: “DFUs from poor sensation/healing; education saves limbs.”
  • Impact: Targets India’s 77M diabetics; promotes MDT for 80% 6-week healing.

Read full article

Keywords: World Diabetes Day, diabetic foot ulcers, PGIMER, amputation prevention, patient education

Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins ….



Orpyx Medical Technologies Supplies Digital Health Platform for NIH-Funded and Johns Hopkins Medicine-Led Clinical Trial on Diabetic Foot Ulcer Prevention

Summary:** Orpyx Medical Technologies is supplying its Smart Footwear Technology (SFT) platform for an NIH-funded, Johns Hopkins-led Phase 2 trial on DFU prevention in high-risk diabetics. The sensor insole monitors plantar pressure, activity, and temperature in real-time, using AI to predict ulcers and alert users/providers. With 15% DFU risk and 20% amputation rate, the trial aims to generate evidence for digital tools in reducing incidence, potentially integrating with EHRs for proactive care.

Key Highlights:

  • SFT Platform: Insole sensors track pressure hotspots, steps, and temp for ulcer prediction.
  • Trial: Phase 2, NIH-funded; Johns Hopkins lead; focuses on high-risk diabetics.
  • AI Analytics: Alerts for risk; integrates with apps for user education.
  • Impact: Targets 50% recurrence; evidence for digital prevention in DFU management.
  • Quote: “High-quality evidence to inform digital tools’ role in DFU prevention.”

Read full article

Keywords: Orpyx SFT, DFU prevention, NIH trial, Johns Hopkins, smart footwear

A Novel Approach to Diabetes-Related Foot Ulcers/Disease



A Novel Approach to Diabetes-Related Foot Ulcers/Disease: First Report of Bipolar Pulsed RF Lumbar Sympathectomy

Summary: This retrospective cohort of 31 DFU patients with critical limb ischemia ineligible for revascularization underwent bipolar pulsed radiofrequency (RF) lumbar sympathectomy, achieving 60% wound closure, significant pain reduction (VAS 7.2 to 2.1), and improved ABI (0.6 to 0.8). Performed under fluoroscopy, the procedure disrupts sympathetic nerves to enhance perfusion without surgery, with 80% limb salvage at 12 months. As first report, it offers a safe, minimally invasive adjunct for refractory DFUs, warranting RCTs.

Key Highlights:

  • Cohort: 31 patients (mean age 62, 65% male); Wagner II-IV DFUs; ABI <0.7.
  • Procedure: RF at L2-L3 under fluoroscopy; 80% sympathectomy success.
  • Outcomes: 60% closure at 3 months; pain VAS drop 5.1; no major AEs.
  • Follow-Up: 80% AFS at 12 months; improved transcutaneous O2.
  • Authors: Iida O et al. (Nov 13, 2025).

Read full article

Keywords: bipolar RF, lumbar sympathectomy, diabetes foot ulcers, perfusion, limb ischemia, O Iida, T Yokoi, M Kato

National Diabetes Foot Care Audit 2020 to 2025



National Diabetes Foot Care Audit 2020 to 2025

Summary: The NHS England National Diabetes Foot Care Audit (NDFA) 2020-2025 reports DFU episode registration rates varying from 0.5 to 2.5 per 100 person-years across Integrated Care Boards (ICBs), with 16% of audited patients having active ulcers and 70% receiving vascular assessments. Data from 100,000+ records highlights disparities in care, with only 60% of high-risk patients having annual reviews. The audit calls for improved data submission (only 50% ICBs fully compliant) to benchmark and reduce amputation rates, supporting the 2025 goal of 80% ulcer healing within 6 weeks.

Key Highlights:

  • Episode Rates: 0.5-2.5/100 person-years; 16% active ulcers in audited cohort.
  • Care Metrics: 70% vascular assessment; 60% high-risk annual reviews; 50% ICB data compliance.
  • Variations: Urban ICBs higher rates; rural gaps in podiatry access.
  • Recommendations: Mandatory annual audits; MDT for high-risk; digital tools for tracking.
  • Impact: Aims to cut amputations 20% by 2025 through data-driven prevention.

Read full article

Keywords: NHS audit, diabetic foot care, DFU episodes, ICB variations, ulcer prevention

A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency



A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

Summary: This narrative review examines the multifactorial pathogenesis of diabetic foot ulcers (DFUs), affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, peripheral neuropathy, hyperglycemia-induced immune defects, and microbial dysbiosis with biofilms. It discusses diagnostic tools (ABI, TCOM, biopsy) and evidence-based therapies from offloading/compression (TCCs 80% efficacy) to advanced interventions like HBOT (50% closure), growth factors, stem cells, and bioengineered skins (50-70% rates). Microbial shifts (Staphylococcus dominance) exacerbate inflammation; the review advocates personalized, multidisciplinary strategies with AI diagnostics and nanotech antimicrobials to mitigate global burden and enhance limb salvage.

Key Highlights:

  • Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection in 60% of cases.
  • Immune Dysbiosis: Hyperglycemia promotes M1 macrophages; biofilms resist antibiotics in 50% of infected DFUs.
  • Therapies: Offloading (TCCs 80%); HBOT (50% closure); bioengineered skins (70% in RCTs).
  • Future: AI for risk prediction; microbiome modulation with phages; nanotech for targeted delivery.
  • Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading cuts risk 50%.

Read full article

Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins, Abdullah Al-Rubaish, Mohammed Al-Rubaish, Ahmad Al-Rubaish

Current Trends in Single-Cell RNA Sequencing Applications in Diabetes Mellitus



Current Trends in Single-Cell RNA Sequencing Applications in Diabetes Mellitus

Summary:** This review surveys single-cell RNA sequencing (scRNA-seq) trends in diabetes research, including DFU pathogenesis, where it uncovers heterogeneous cell responses like dysfunctional macrophages and fibrotic fibroblasts. In DFUs, scRNA-seq identifies T cell exhaustion and ECM dysregulation, with 85% accuracy in predicting non-healing via gene clusters. Emerging applications include spatial transcriptomics for ulcer microenvironments, guiding precision therapies like macrophage reprogramming to enhance granulation and closure.

Key Highlights:

  • scRNA-seq Reveals: Macrophage M1 shift in DFUs; fibroblast senescence clusters.
  • DFU Insights: 85% non-healing prediction; links to neuropathy/vascular defects.
  • Trends: Spatial scRNA for ulcer edges; multi-omics integration for biomarkers.
  • Therapeutics: Targets like CTSH for ECM repair; 40% faster healing in models.
  • Future: Personalized DFU trials using scRNA for cell-specific drugs.

Read full article

Keywords: single cell RNA, diabetes mellitus, DFU pathogenesis, macrophage dysfunction, spatial transcriptomics

Endovascular Treatment Outcomes for TASC C and D Lesions in Chronic Peripheral Arterial Disease



Endovascular Treatment Outcomes for TASC C and D Lesions in Chronic Peripheral Arterial Disease

Summary:** This meta-analysis of 15 studies (n=1,200) evaluates endovascular therapy (EVT) for TASC C/D infrapopliteal lesions in chronic limb-threatening ischemia (CLTI) with DFUs, showing 70% limb salvage at 1 year and 60% patency. EVT outperforms bypass in short-term (6 months) wound healing (OR 1.5) but similar long-term amputation-free survival. Complications like restenosis (30%) highlight need for adjuncts like stents; EVT is preferred for high-risk patients to facilitate ulcer closure.

Key Highlights:

  • Outcomes: 70% limb salvage; 60% primary patency; 50% wound healing at 6 months.
  • EVT vs Bypass: Better short-term healing; equivalent 1-year AFS (80%).
  • DFU Impact: Revascularization boosts closure 40%; stents reduce restenosis 25%.
  • Limitations: Heterogeneity; short follow-up; calls for RCTs in DFU cohorts.
  • Implications: Guides EVT for TASC C/D in PAD with ulcers.

Read full article

Keywords: endovascular therapy, TASC lesions, CLTI, limb salvage, DFU revascularization

Multi-Omics Identification of Activated T Cells and Spatial PD-1/PD-L1 Signaling as Biomarkers ….



Multi-Omics Identification of Activated T Cells and Spatial PD-1/PD-L1 Signaling as Biomarkers of Diabetic Foot Ulcer Healing

Summary:** This bioRxiv preprint uses multi-omics (scRNA-seq, proteomics, spatial transcriptomics) to identify activated T cells and PD-1/PD-L1 signaling as key biomarkers for DFU healing. In 20 patients, non-healing ulcers showed exhausted T cells with high PD-L1 expression in fibroblasts, correlating with poor granulation. PD-1 blockade in ex vivo models boosted migration 40%, suggesting immune checkpoint inhibitors as adjuncts for refractory DFUs, with potential for personalized immunotherapy.

Key Highlights:

  • Omics Data: scRNA-seq reveals T cell exhaustion signature in non-healers (PD-1+ CD8+).
  • Spatial Signaling: PD-L1 in stromal cells suppresses T cell function at ulcer edges.
  • Validation: Ex vivo blockade enhances keratinocyte proliferation and VEGF.
  • Biomarker: PD-1/PD-L1 ratio predicts 70% of healing variance.
  • Implications: Targets immune therapy for stalled DFUs; clinical trials needed.

Read full article

Keywords: multi omics, T cells, PD-1 PD-L1, DFU biomarkers, immune exhaustion

Finite Element Analysis of Biomechanical Effects in Rat Tibia During Tibial ….



Finite Element Analysis of Biomechanical Effects in Rat Tibia During Tibial Cortex Transverse Fracture for DFU Modeling

Summary:** This study develops and validates a finite element (FE) model of rat tibial cortex transverse fracture to simulate biomechanical stresses in diabetic foot ulcer (DFU) pathogenesis, incorporating hyperglycemia and neuropathy effects. The model accurately predicts von Mises stress (peak 12 MPa) and strain (4%) in fracture sites, correlating with delayed healing in diabetic rats. It highlights offloading’s role in reducing peak stress by 30%, offering a tool for preclinical testing of DFU interventions like scaffolds or electrical stimulation.

Key Highlights:

  • Model: CT-based FE of rat tibia; simulates transverse fracture under 50N load.
  • Diabetes Effects: Hyperglycemia increases bone fragility, elevating stress 25% vs controls.
  • Validation: Correlates with in vivo strain gauges (r=0.92); predicts 40% delayed union.
  • Implications: Guides DFU offloading designs; tests biomaterials for stress reduction.
  • Authors: Li et al. (Nov 12, 2025).

Read full article

Keywords: finite element analysis, diabetic foot ulcer, rat tibia model, biomechanical stress, offloading

A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency ….



A Comprehensive Review on Diabetic Foot Ulcer Addressing Vascular Insufficiency, Impaired Immune Response, and Microbial Dysbiosis

Summary: This narrative review synthesizes DFU’s complex etiology, affecting 15-25% of diabetics and leading to 85% of amputations, driven by vascular insufficiency, neuropathy, hyperglycemia-induced immune defects, and biofilms. It covers diagnostic tools (TCOM, ABI, biopsy) and therapies from offloading/compression to advanced options like growth factors, stem cells, and bioengineered skins (50-70% closure rates). Microbial dysbiosis (e.g., Staphylococcus dominance) exacerbates inflammation; the review calls for personalized, multidisciplinary approaches with AI diagnostics and nanotech antimicrobials to reduce global burden and enhance limb salvage.

Key Highlights:

  • Vascular/Neuropathy: Ischemia impairs perfusion; neuropathy masks pain, delaying detection.
  • Immune Dysbiosis: Hyperglycemia shifts macrophages to M1; biofilms (Staph/Pseudomonas) resist antibiotics.
  • Therapies: Offloading (TCCs 80% efficacy); HBOT (50% closure); bioengineered skins (70% in RCTs).
  • Future: AI for risk prediction; nanotech for targeted delivery; microbiome modulation.
  • Burden: $15B U.S. cost; 1M global amputations/year; prevention via screening/offloading.

Read full article

Keywords: diabetic foot ulcer, vascular insufficiency, immune response, microbial dysbiosis, bioengineered skins

Royal Jelly for Diabetic Wound Healing: A Natural Approach



Royal Jelly for Diabetic Wound Healing: A Natural Approach (2025)

Summary:** Royal jelly (RJ), a bee secretion rich in antioxidants and growth factors, shows promise for diabetic wound healing through antimicrobial, anti-inflammatory, and regenerative properties. Topical RJ reduces oxidative stress, promotes collagen synthesis, and accelerates closure in DFU models by 30-50%, with low cytotoxicity. The review explores RJ-derived EVs for enhanced delivery, positioning it as a cost-effective adjunct to standard care for infection-prone ulcers.

Key Highlights:

  • Composition: 10-HDA, proteins, flavonoids for antibacterial (vs E. coli/Staph) and antioxidant effects.
  • DFU Benefits: Boosts fibroblast proliferation, VEGF for angiogenesis; 40% faster healing in rats.
  • Delivery: Topical gels or EVs for sustained release; no allergies in diabetics.
  • Evidence: Preclinical; human trials needed for dosing.
  • Implications: Natural, affordable for global DFU management.

Read full article

Keywords: royal jelly, diabetic wound, antimicrobial, collagen synthesis, natural therapy

How Can Wound Care RCM Build a Denial-Proof Revenue Cycle?



How Can Wound Care RCM Build a Denial-Proof Revenue Cycle?

Summary:** Wound care revenue cycle management (RCM) faces unique challenges like variable payer rules, documentation gaps, and denials (30-50% for DFUs), but real-time analytics can cut AR by 40% by tracking patterns, automating appeals, and ensuring compliance. MBC’s dashboard monitors denial reasons (e.g., medical necessity for grafts), provider delays, and CPT coding, with outsourcing offering expertise in modifiers and prior auths to boost collections and reduce write-offs in chronic ulcer billing.

Key Highlights:

  • Challenges: 40% denials from poor documentation; variable coverage for biologics.
  • Analytics: Tracks AR buckets, denial codes, payer trends for proactive fixes.
  • Strategies: Automated appeals, coder training, payer-specific guidelines.
  • Outcomes: 42% AR reduction in client; 95% first-pass claims.
  • Outsourcing: MBC provides end-to-end for wound care, including audits.

Read full article

Keywords: wound care RCM, denial management, AR reduction, CPT coding, ulcer billing

Fish Collagen Technology Brings a Breakthrough in the Healing of Hard-to-Heal Wounds



TAICEND’s Patented Fish Collagen Technology Brings a Breakthrough in the Healing of Hard-to-Heal Wounds

Summary: TAICEND Technology unveiled its patented fish collagen series at Medica 2025, leveraging molecular medicine to accelerate hard-to-heal wound recovery by over 50%. The Postoperative, Acute & Chronic, Pressure Relief, Skin Protection, and Trauma series target stalled healing through cellular insights, providing protocol-driven solutions for clinical and home use. Fish collagen’s biocompatibility and self-repair properties offer sustainable alternatives to synthetic options, with SOPs clinically proven for faster granulation in pressure ulcers and DFUs.

Key Highlights:

  • Series: Postoperative for infection/scar reduction; Chronic for pressure ulcers (50%+ healing speed).
  • Technology: Fish collagen integrates cellular activity for moist healing and biofilm control.
  • Applications: Home/long-term care; Trauma for emergencies with tourniquets/chest seals.
  • Event: Medica 2025 booth; CEO: “From stalled to accelerated recovery.”
  • Impact: Sustainable, protocol-driven; fosters global collaboration.

Read full article

Keywords: fish collagen, hard to heal wounds, TAICEND, postoperative care, Medica 2025

NeXtGen Biologics and Lovell Government Services Partner to Bring Innovative Advanced Wound Care …



NeXtGen Biologics and Lovell Government Services Partner to Bring Innovative Advanced Wound Care Technology to Federal Healthcare Systems

Summary:** NeXtGen Biologics and Lovell Government Services announced a partnership to supply advanced wound care technologies to federal healthcare systems, including VA and military facilities. The collaboration focuses on regenerative products for chronic wounds like DFUs, leveraging Lovell’s distribution expertise to improve access and outcomes for veterans and active-duty personnel, reducing healing times and amputation risks through evidence-based innovations.

Key Highlights:

  • Partnership: NeXtGen’s biologics via Lovell’s federal contracts for VA/military wound care.
  • Products: Regenerative grafts and dressings for DFUs and pressure ulcers.
  • Impact: Faster healing, lower costs; targets 1M+ veterans with chronic wounds.
  • Quote: “Enhances care for those who’ve served; innovation meets need.”
  • Date: Nov 10, 2025; Alachua, FL announcement.

Read full article

Keywords: NeXtGen Biologics, Lovell Government, federal wound care, VA patients, regenerative products

Game-Changing Alliance: Adia Labs and Axia Women’s Health



Game-Changing Alliance: Adia Labs and Axia Women’s Health

Summary:** Adia Nutrition Inc. announced a strategic alliance with Axia Women’s Health to integrate insurance-billable wound care products into Adia’s expanding network of Med clinics, specializing in orthopedic, pain management, and diabetic wound repair. The partnership leverages AdiaLabs’ lab division for advanced testing and therapies, aiming to address chronic wounds in women’s health while pursuing Nasdaq uplisting. With 13M U.S. diabetics at risk for ulcers, the collaboration enhances access to regenerative treatments and nutrition-focused care.

Key Highlights:

  • Partnership Focus: Wound care products for diabetic ulcers in Adia Med clinics.
  • Expansion: Nationwide growth with Axia for women’s health integration.
  • AdiaLabs: Billable diagnostics for personalized wound therapies.
  • Impact: Targets 50% infected DFUs; improves outcomes via nutrition/repair.
  • Financial: $5M+ funding; Nasdaq uplisting by 2026.

Read full article

Keywords: Adia Nutrition, Axia Women’s Health, wound care partnership, diabetic repair, insurance billable

FDA Grants Rare Pediatric Disease Designation for CCP-020 for Treatment of Epidermolysis Bullosa



FDA Grants Rare Pediatric Disease Designation for CCP-020 for Treatment of Epidermolysis Bullosa

Summary:** Castle Creek Biosciences received FDA Rare Pediatric Disease Designation for CCP-020, a topical formulation of clobetasol propionate for epidermolysis bullosa (EB), a genetic disorder causing fragile skin and chronic blisters/ulcers. Affecting ~1 in 20,000 births, EB leads to painful wounds requiring daily bandaging; CCP-020 aims to reduce blistering and inflammation. The designation accelerates review and grants a priority review voucher upon approval, supporting development for this orphan condition with no curative treatments beyond supportive wound care.

Key Highlights:

  • CCP-020: Topical clobetasol for EB blister reduction and wound prevention.
  • Rare Designation: For conditions <200,000 U.S. cases; prioritizes review and incentives.
  • EB Burden: Chronic wounds, infections, 30% mortality by age 35 from skin cancer.
  • Development: Phase 2 trials ongoing; voucher aids funding for rare disease therapies.
  • Implications: Advances EB wound management beyond dressings and pain control.

Read full article

Keywords: CCP-020, epidermolysis bullosa, rare pediatric disease, clobetasol, EB blisters

Net Health NEXT 2026 Sets the Stage for AI-Powered, Human-Centered Care



Net Health NEXT 2026 Sets the Stage for AI-Powered, Human-Centered Care

Summary:** Net Health’s NEXT 2026 conference (March 4-6, Nashville) spotlights AI integration in wound care, with roadmaps for DFU management, rehab therapy, and occupational health. Sessions cover AI-driven EHRs for faster documentation, predictive analytics for ulcer prevention, and human-centered design to enhance clinician efficiency. Over 30 years of expertise inform the event, featuring keynotes like CTO Raj Grover on AI roadmaps and workshops on performance metrics, aiming to streamline care and reduce administrative burdens in chronic wound treatment.

Key Highlights:

  • Theme: AI for human-centered care; sessions on wound, rehab, and occupational health EHRs.
  • Roadmaps: DFU analytics for risk prediction; AI for therapy outcomes and compliance.
  • Keynotes: CTO Raj Grover on innovation; workshops/case studies for practical implementation.
  • Impact: Reduces admin time 30%; improves accuracy in ulcer assessment.
  • Date/Location: March 4-6, 2026, Nashville; registration open.

Read full article

Keywords: AI wound care, Net Health conference, DFU management, EHR innovation, rehab therapy

CMS Finalizes Sweeping Reforms to Skin Substitute Payments Amid Rising Costs and Enforcement Concerns



CMS Finalizes Sweeping Reforms to Skin Substitute Payments Amid Rising Costs and Enforcement Concerns

Summary: CMS has finalized significant reforms to skin substitute payments under the 2026 Medicare Physician Fee Schedule, establishing a flat rate of $127.28 per square centimeter for most products used in non-facility and hospital outpatient settings. Based on Q4 2024 data, the methodology addresses a 40-fold payment increase over five years, driven by fraud and overutilization in wound care. Biologicals under section 351 retain ASP reimbursement, and the changes do not affect the WISeR model or upcoming LCDs for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). Providers must review product-specific limits to ensure compliance, with potential ripple effects on access for chronic wound treatments.

Key Highlights:

  • Payment Model: Flat $127.28/cm² for skin substitutes in Part B non-facility/HOPD professional fees, effective Jan 1, 2026.
  • Rationale: Curb $15B projected 2025 spend (up 50% from 2024) due to fraud/overuse in wound care.
  • Exceptions: Section 351 biologicals use ASP; application services reimbursed separately.
  • No Impact: WISeR model and DFU/VLU LCDs unchanged; encourages product review via ASP files.
  • Enforcement: Ties to DOJ actions on $2B+ graft fraud; providers urged to audit for necessity.

Read full article

Keywords: skin substitute reforms, CMS payment, diabetic foot ulcers, venous leg ulcers, fraud crackdown

Use of Electrical Stimulation Therapy to Reduce Pain Associated with Hard-to-Heal Wounds



Use of Electrical Stimulation Therapy to Reduce Pain Associated with Hard-to-Heal Wounds

Summary:** This abstract reviews electrical stimulation (ES) as an adjunctive therapy to reduce pain in hard-to-heal wounds, including diabetic foot ulcers, with a meta-analysis of RCTs showing significant pain reduction and improved healing rates. ES modulates nerve signals and promotes circulation, but the full text is paywalled, limiting details on methods, outcomes, or specific DFU data. It positions ES as safe and effective for refractory pain, warranting further study in chronic wound care.

Key Highlights:

  • ES as adjunct for pain in hard-to-heal wounds like DFUs.
  • Meta-analysis: RCTs show reduced pain and accelerated healing.
  • Mechanisms: Nerve modulation, improved perfusion.
  • Implications: Ethical, low-risk; calls for standardized protocols.
  • DOI: 10.12968/jowc.2024.0235 (paywalled).

Read full article

Keywords: electrical stimulation, wound pain, hard to heal ulcers, adjunctive therapy, meta analysis

Wound Care Training Gap in Medical Schools



Chronic Wounds in Home Health: The Training Gap

Summary:** Chronic wounds affect 6.5M Americans, costing $25B/year, yet medical schools provide <5 hours of wound care training, leading to misdiagnosis and delayed care in home health settings. The article highlights DFUs and pressure ulcers as common home health challenges, with 40% non-healing due to inadequate education on debridement, offloading, and infection signs. It advocates for mandatory curricula, simulation training, and certification to empower nurses and reduce 20% amputation rates in diabetics.

Key Highlights:

  • Training Shortfall: <5 hours in med schools; no national mandate for nursing.
  • Impact: 50% DFUs non-healing; pressure ulcers 60,000 deaths/year from neglect.
  • Home Health Role: Nurses handle 80% wound care; lack training leads to readmissions.
  • Solutions: Simulation, certification; 52% better outcomes with trained staff.
  • Call: Reform curricula; integrate with home health protocols.

Read full article

Keywords: wound care training, medical schools, home health, DFU management, curriculum reform

Osteomyelitis in Pressure Ulcers



Osteomyelitis in Pressure Ulcers

Summary:** This best practice statement (BPS) from Wounds UK addresses osteomyelitis in pressure ulcers, affecting 20-30% of deep cases, with guidelines for diagnosis (MRI preferred, 90% sensitivity), treatment (6-12 weeks antibiotics, debridement for exposed bone), and prevention (offloading, nutrition). It emphasizes MDT care for 70% healing rates, reducing amputation risks, and calls for training to recognize symptoms like sinus tracts in pressure ulcers.

Key Highlights:

  • Diagnosis: MRI for bone edema; probe-to-bone test 80% accurate; biopsy for culture.
  • Treatment: IV antibiotics (vancomycin for MRSA); surgical debridement for 50% faster resolution.
  • Prevention: Weekly pressure relief; nutrition (albumin >3g/dL); offloading 80% compliance.
  • Outcomes: 70% healing with MDT; 20% amputation if untreated.
  • Implications: BPS for pressure ulcer protocols; training for GPs/nurses.

Read full article

Keywords: osteomyelitis, pressure ulcers, MRI diagnosis, antibiotic therapy, debridement

Wound Care Transformation in Wales – Digital Empowerment and the Skin Tone Tool



Wound Care Transformation in Wales – Digital Empowerment and the Skin Tone Tool

Summary:** Wales is transforming wound care through digital tools and the Skin Tone Tool, addressing disparities in pressure ulcer and DFU assessment. The tool—integrated into e-health records—standardizes skin color-inclusive evaluation, reducing misdiagnosis in darker tones and improving prevention via real-time risk alerts. Early adopters report 20% better detection rates and 15% fewer incidents, aligning with NHS Wales’ digital strategy for equitable care.

Key Highlights:

  • Skin Tone Tool: 6-tone scale in digital charts for accurate pressure ulcer/DFU assessment.
  • Digital Integration: Alerts for risk; training for 90% staff; 20% improved detection.
  • Impact: Reduces disparities in darker skin; 15% fewer ulcers via early intervention.
  • Policy: NHS Wales mandates for 2025; supports pressure ulcer prevention protocols.
  • Future: National rollout; links to telemedicine for remote wound monitoring.

Read full article

Keywords: skin tone tool, digital wound care, pressure ulcer, inclusive assessment, Wales NHS

Medicare Advantage Reimbursement Structures Impact Home Health Delivery and Outcomes



Medicare Advantage Reimbursement Structures Impact Home Health Delivery and Outcomes

Summary:** This study analyzes how Medicare Advantage (MA) payment models affect home health agency (HHA) delivery for wound care, finding MA patients receive 20% fewer visits and 15% higher costs due to prior authorizations and lower reimbursements vs fee-for-service. For pressure ulcers and surgical wounds, MA delays care (e.g., dressing changes), leading to 10% higher readmissions. Recommendations include streamlined approvals and value-based adjustments to improve outcomes for diabetic and elderly patients.

Key Highlights:

  • MA vs FFS: 20% fewer visits; 15% higher costs for wound care services.
  • Wound Impact: Pressure ulcers/surgical wounds in MA patients show 10% slower healing.
  • Barriers: Prior auth delays (50% of claims); lower per-visit rates.
  • Solutions: National standards for approvals; HHA incentives for MA patients.
  • Implications: Affects 50% Medicare; calls for policy reform to protect vulnerable wounds.

Read full article

Keywords: Medicare Advantage, home health, wound outcomes, prior authorization, pressure ulcers

Wound Care in the UK: Addressing Variations in Practice, Cost …



Wound Care in the UK: Addressing Variations in Practice, Cost, Outcomes, and the Data Deficit

Summary:** This review examines variations in UK wound care practice, estimating 2.2 million cases (3.4% population) costing £5.3 billion annually, with 30% waste from inconsistent data and guidelines. Pressure ulcers alone cost £2.9B, DFUs £650M; data gaps hinder benchmarking, leading to suboptimal healing (50% DFUs close in 12 weeks). It advocates national registries, standardized assessment (e.g., TIME), and MDT protocols to cut costs 20-40% and improve outcomes, emphasizing the need for robust evidence to address the “data deficit.”

Key Highlights:

  • Prevalence: 3.4% UK population; 2M+ wounds; pressure ulcers 700,000 cases/year.
  • Costs: £5.3B total; 30% waste from poor data; DFUs £650M, leg ulcers £2.3B.
  • Variations: Inconsistent assessment (50% use PUSH); regional differences in healing rates.
  • Solutions: National database, MDT care, standardized guidelines for 52% better outcomes.
  • Implications: Addresses waste; improves equity in diabetic/pressure ulcer management.

Read full article

Keywords: UK wound care, practice variations, data deficit, pressure ulcers, cost reduction

Biodegradable Temporising Matrix in Diabetic Foot Ulcer Management



Biodegradable Temporising Matrix in Diabetic Foot Ulcer Management

Summary:** This review evaluates biodegradable temporising matrix (BTM)—a 3D scaffold of medical-grade bovine collagen—for wound bed preparation in diabetic foot ulcers (DFUs), where vascular disease delays healing. BTM facilitates granulation in 60-80% of cases within 2-4 weeks, supporting skin grafting or closure, with 90% graft take rates. As adjunct to debridement/offloading, it reduces infection risks and amputation in 70% of Wagner III-IV DFUs, though challenges include cost and infection in ischemic wounds.

Key Highlights:

  • BTM Structure: 98% type I collagen scaffold promotes fibroblast migration and vascularization.
  • DFU Application: Ordered in 4-6 weeks post-debridement; 60-80% granulation; 90% graft success.
  • Evidence: 70% limb salvage in advanced DFUs; reduced hospital stays vs. standard care.
  • Challenges: Contraindicated in active infection; cost $500-1000 per application.
  • Implications: Ideal for refractory DFUs; future with growth factors for enhanced regeneration.

Read full article

Keywords: biodegradable matrix, diabetic foot ulcer, BTM, granulation, limb salvage

Quick Guide: Cutimed® Sorbact® and Antimicrobial Stewardship



Quick Guide: Cutimed® Sorbact® and Antimicrobial Stewardship

Summary:** This free quick guide from Wounds UK and BSN Medical details Cutimed Sorbact dressings’ role in antimicrobial stewardship for chronic wounds, using a bacterial binding mechanism to remove biofilms without antimicrobials, reducing infection risks in DFUs and VLUs. It covers application, evidence (e.g., 70% bacterial reduction), and stewardship principles like delayed antibiotic use, supporting NHS guidelines for waste reduction and resistance prevention.

Key Highlights:

  • Mechanism: Sorbact technology binds bacteria via hydrophobic interactions, removing 2.4 log10 CFU in vitro.
  • Evidence: RCTs show 50% faster healing in colonized wounds; no resistance development.
  • Stewardship: Aligns with NICE; delays systemic antibiotics, reduces hospital stays 20%.
  • Application: For low-moderate exudate; change 2-7 days; compatible with NPWT.
  • Download: Free PDF with protocols for DFU/VLU management.

Read full article

Keywords: Cutimed Sorbact, antimicrobial stewardship, biofilm removal, chronic wounds, resistance prevention

Use of Electrical Stimulation Therapy to Reduce Pain Associated with Hard-to-Heal Wounds



Use of Electrical Stimulation Therapy to Reduce Pain Associated with Hard-to-Heal Wounds

Summary:** This abstract reviews electrical stimulation (ES) as an adjunctive therapy to reduce pain in hard-to-heal wounds, including diabetic foot ulcers, with a meta-analysis of RCTs showing significant pain reduction and improved healing rates. ES modulates nerve signals and promotes circulation, but the full text is paywalled, limiting details on methods, outcomes, or specific DFU data. It positions ES as safe and effective for refractory pain, warranting further study in chronic wound care.

Key Highlights:

  • ES as adjunct for pain in hard-to-heal wounds like DFUs.
  • Meta-analysis: RCTs show reduced pain and accelerated healing.
  • Mechanisms: Nerve modulation, improved perfusion.
  • Implications: Ethical, low-risk; calls for standardized protocols.
  • DOI: 10.12968/jowc.2024.0235 (paywalled).

Read full article

Keywords: electrical stimulation, wound pain, hard to heal ulcers, adjunctive therapy, meta analysis

Diabetes Breakthrough: Sound Waves Offer New Hope for Foot Ulcers



Diabetes Breakthrough: Sound Waves Offer New Hope for Foot Ulcers

Summary:** Non-invasive sound wave therapy accelerates diabetic foot ulcer (DFU) healing by stimulating tissue regeneration and blood flow, considered an adjunct to standard wound care like debridement. While details on trial size/methods are limited, it reduces infection risks and may lessen surgery needs, improving quality of life and amputation prevention in diabetics. The approach builds on sound wave applications in medicine, positioning it as a safe, non-invasive option for chronic ulcers.

Key Highlights:

  • Mechanism: Sound waves enhance circulation and cellular repair in stalled DFUs.
  • Role: Adjunct to debridement/dressings; considered free of side effects.
  • Outcomes: Faster healing; potential to cut amputation risks in diabetics.
  • Expert View: Considered adjunct, not replacement; complements traditional care.
  • Implications: Improves mobility/QoL; broader medical applications for sound waves.

Read full article

Keywords: sound wave therapy, diabetic foot ulcers, non invasive, amputation prevention, adjunct therapy

Topical Melatonin Boosts Healing in Diabetic Foot Ulcers



Topical Melatonin Boosts Healing in Diabetic Foot Ulcers

Summary:** A double-blind RCT by Ahmadvash et al. (BMC Endocrine Disorders, 2025) evaluated topical melatonin as adjunct for diabetic foot ulcers (DFUs), showing greater ulcer size reductions and higher healing rates vs placebo, with no significant adverse effects. Melatonin’s antioxidant properties reduce oxidative stress in fibroblasts, enhance enzyme activity, hydrate wound beds, and modulate immunity to prevent infection, positioning it as a safe, affordable add-on to standard debridement/dressings. Limitations include small sample; larger trials needed for dosing/long-term effects.

Key Highlights:

  • Design: Randomized to melatonin or placebo; primary: % ulcer area reduction; secondary: AEs, pain/comfort.
  • Outcomes: Melatonin group had greater size reductions and “markedly higher” healing rates; well-tolerated.
  • Mechanisms: Reduces fibroblast oxidative stress; boosts antioxidant enzymes; hydrates/promotes immune balance.
  • Implications: Adjunct for DFUs; complements debridement; potential for 50%+ faster closure.
  • Authors: Ahmadvash F, Gharabagh LH, Emami S et al.

Read full article

Keywords: topical melatonin, diabetic foot ulcer, antioxidant, RCT, oxidative stress

Biological Mechanisms and Clinical Challenges of Platelet-Rich Plasma in Chronic Musculoskeletal Pain and Wound Care



Biological Mechanisms and Clinical Challenges of Platelet-Rich Plasma in Chronic Musculoskeletal Pain and Wound Care

Summary: This review examines platelet-rich plasma (PRP)’s mechanisms—growth factor release (PDGF, TGF-β, VEGF) for immunomodulation and tissue repair—in chronic musculoskeletal pain and wound healing, including DFUs. PRP accelerates re-epithelialization and fibroblast migration in wounds, but 40% of DFU trials fail due to unregulated preparation (centrifugation 1500–3000 rpm, anticoagulant variability), yielding inconsistent platelet concentrations (500,000–1,500,000/μL) and growth factor release. A 2024 meta-analysis confirms instability; multi-omics (genomics/proteomics) is proposed for precision PRP, emphasizing standardization to overcome reproducibility issues in diabetic ulcer management.

Key Highlights:

  • Mechanisms: PRP releases EGF/VEGF for angiogenesis; supports fibroblast migration in DFUs.
  • Challenges: 40% negative DFU outcomes from variable PRP (Ajay 2021); Peng meta-analysis (2024) confirms.
  • Training Gap: Unregulated kits lead to waste; multi-omics for personalized dosing.
  • Implications: Standardize for chronic wounds; potential 52% efficacy boost with optimization.
  • Authors: Haizhou Zhou, Qianjie Huang, Yichao Chen, Jianmin Wang, Hui Jiang (Nov 7, 2025).

Read full article

Keywords: platelet rich plasma, diabetic ulcer, PRP variability, growth factors, multi omics

Research Progress on the Role and Mechanisms of Ferroptosis in Diabetic Wound Repair



Research Progress on the Role and Mechanisms of Ferroptosis in Diabetic Wound Repair

Summary: This review explores ferroptosis—an iron-dependent cell death driven by lipid peroxidation and antioxidant dysregulation—as a key contributor to delayed diabetic wound healing, particularly in diabetic foot ulcers (DFUs). High-glucose environments exacerbate ferroptosis in repair cells (macrophages, fibroblasts, endothelial cells, keratinocytes), disrupting inflammation, angiogenesis, and re-epithelialization. Mechanisms include Fenton reactions from Fe²⁺, PUFA peroxidation via ACSL4/lipoxygenases, and impaired GPX4/GSH defenses. Therapeutic inhibition with Ferrostatin-1, deferoxamine, or natural compounds (resveratrol, PRP, MSC-EVs) reduces ferroptosis, enhancing granulation and closure in diabetic models, while activation targets bacterial biofilms. The review calls for clinical trials on ferroptosis biomarkers and multimodal therapies to overcome DFU chronicity.

Key Highlights:

  • Ferroptosis disrupts diabetic healing via iron overload, ROS, and GPX4 inhibition; key in DFU refractory cases.
  • Cell-specific effects: Macrophages shift to M1; fibroblasts impair ECM; endothelial cells reduce VEGF; keratinocytes delay migration.
  • Inhibitors like Ferrostatin-1 or 4-octyl itaconate accelerate closure 40-60% in diabetic rats by boosting Nrf2/GPX4.
  • Bacterial role: Ferroptosis-sensitive pathogens (E. coli) cleared by iron-loaded hydrogels; aids infection control.
  • Implications: Ferroptosis as DFU biomarker; training for multimodal (topical/systemic) interventions needed.

Read full article

Keywords: ferroptosis, diabetic wound, lipid peroxidation, GPX4, DFU therapy

How Real-Time Analytics Can Cut Wound Care AR by 40%



How Real-Time Analytics Can Cut Wound Care AR by 40%

Summary: The article explains how real-time analytics can reduce accounts receivable (AR) aging in wound care by up to 40% by addressing challenges like frequent prior authorization denials, variable payer coverage, delayed physician documentation, and overlapping services. MBC’s dashboard provides live insights into denial patterns by payer and procedure, aging claims by bucket, provider-level documentation lags, and regional trends. This enables faster prioritization of high-risk claims, automated denial workflows, coder retraining, and monitoring of clinic performance. A client example showed a 42% reduction in AR over 90 days without EHR changes. MBC offers integrated analytics with existing systems, dedicated support, and full wound care billing services to improve collections and reduce write-offs.

Key Highlights:

  • Tracks denials by payer, procedure, and CPT codes to identify issues instantly.
  • Highlights aging claims in 91–120+ day buckets to prioritize and prevent write-offs.
  • Monitors provider documentation delays to speed up billing processes.
  • Identifies underperforming clinics or regions for targeted improvements.
  • Connects analytics to billing actions like CPT codes, modifiers, and payer rules.

Read full article

Keywords: wound care billing, real-time analytics, AR reduction, denial management, diabetic ulcers

A Retrospective, Observational Case Series of Lower-Extremity Wound ….



A Retrospective, Observational Case Series of Lower-Extremity Wound Management Using CompleteFT

Summary: This retrospective case series evaluates the use of CompleteFT, a full-thickness placental tissue allograft, in managing non-healing lower-extremity wounds in four patients at a Cleveland, Ohio mobile wound center. Seven wounds (sizes 2–440 cm²), including venous leg ulcers (VLUs), non-pressure/traumatic injuries, and pressure injuries, were treated with standard of care plus CompleteFT application, sharp debridement, and secondary dressings. Outcomes showed four wounds healed within two weeks and three exhibited reduced wound surface area within the same period, indicating accelerated healing. The study highlights the adjunctive role of placental allografts in chronic wound management, supporting progress toward healing in diverse lower-extremity ulcer types.

Key Highlights:

  • Four of seven wounds achieved full healing as early as two weeks after CompleteFT application.
  • Three wounds demonstrated a reduction in percent wound surface area within two weeks post-treatment.
  • Wounds treated included venous leg ulcers (n=3), non-pressure/traumatic injuries (n=3), and pressure injuries (n=1).
  • CompleteFT was used alongside regular excisional sharp debridement and secondary wound dressings.
  • Patient cases involved lower-extremity chronic wounds of varying sizes up to 440 cm².

Read full article

Keywords: CompleteFT, placental allograft, venous leg ulcers, wound healing, lower extremity wounds

Rosemary Compound Found to Support Healthy Skin Regeneration After Injury



Rosemary Compound Found to Support Healthy Skin Regeneration After Injury

Summary: Researchers at the Perelman School of Medicine at the University of Pennsylvania found that carnosic acid, an antioxidant in rosemary, enhances skin wound healing in mice by promoting regeneration without scarring. Applied as a cream to the wound site, it accelerates closure, restores hair follicles, oil glands, and cartilage, and activates the TRPA1 nerve sensor essential for scarless healing. Without TRPA1, the effect is lost. Rosemary outperformed other herbs like thyme and oregano in potency and safety, while avoiding irritation seen in alternatives like mustard oil. The study, inspired by social media trends, suggests potential for human wound care, particularly for preventing excessive scarring, though medical consultation is advised before use.

Key Highlights:

  • Carnosic acid from rosemary shifts wound healing from scarring to regeneration in mice.
  • Topical application restores skin structures like hair follicles and oil glands.
  • TRPA1 activation is critical for the scarless healing effect.
  • Effect is localized to the wound site, not distant skin.
  • Rosemary is noted for potency, safety, and accessibility compared to other TRPA1-activating substances.

Read full article

Keywords: rosemary antioxidant, scarless healing, carnosic acid, TRPA1, skin regeneration

Regulatory Update: Calendar Year 2026 Medicare Physician Fee Schedule Final Rule



Regulatory Update: Calendar Year 2026 Medicare Physician Fee Schedule Final Rule (CMS-1832-F)

Summary: The Centers for Medicare and Medicaid Services (CMS) finalized the 2026 Physician Fee Schedule (PFS) rule, introducing a standardized payment model for skin substitute products under Medicare Part B. Published on October 31, 2025, the rule sets a flat rate of $127.28 per square centimeter for these products applied in private offices and the professional component in hospital-based outpatient departments (HOPD). This replaces previous unique payment limits, addressing a cited 40-fold payment increase over five years. Separate reimbursement continues for application services. Exceptions apply to products classified as biologicals under section 351 of the Public Health Service Act. The rule takes effect January 1, 2026, and does not affect the WISeR model or upcoming local coverage determinations (LCDs) for skin substitutes in diabetic foot ulcers and venous leg ulcers.

Key Highlights:

  • Standardizes skin substitute payment at $127.28 per square centimeter for Medicare Part B.
  • Applies to private offices and HOPD professional components, effective January 1, 2026.
  • Addresses prior 40-fold payment increase over five years with a flat rate.
  • Maintains separate reimbursement for product application services.
  • Exceptions for biologicals under Public Health Service Act section 351; no impact on WISeR or LCDs for diabetic/venous ulcers.

Read full article

Keywords: Medicare PFS, skin substitutes, wound care reimbursement, DFUs, VLUs

CMS Announces New Skin Substitute Payment Methodology: Possible Next Steps



CMS Announces New Skin Substitute Payment Methodology: Possible Next Steps

Summary: The Centers for Medicare & Medicaid Services (CMS) finalized a new payment model for skin substitute products under the 2026 Medicare Physician Fee Schedule, effective for Medicare Part B beneficiaries in non-facility and hospital outpatient settings. Payment for most skin substitutes will be a volume-weighted average of $127.28 per square centimeter, based on fourth-quarter 2024 data, while biologicals licensed under section 351 continue using the average sales price (ASP) methodology. This change does not affect the WISeR model or Part B MAC coverage policies for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), set for January 1, 2026. Providers can access ASP pricing files to review product-specific payment limits, many below the average, to inform product selection. Non-Medicare payers may adopt or adapt this methodology.

Key Highlights:

  • New payment model sets volume-weighted average of $127.28 per square centimeter for skin substitutes in 2026.
  • Exception for biologicals licensed under section 351, which retain ASP payment methodology.
  • Payment based on volume-weighted ASP from Q4 2024, using OPPS data for utilization proportions.
  • No impact on WISeR model or MAC coverage criteria for DFUs and VLUs effective January 1, 2026.
  • Providers can check CMS ASP Pricing Files for product-specific payment limits to guide decisions.

Read full article

Keywords: skin substitutes, Medicare payment, diabetic foot ulcers, venous leg ulcers, Physician Fee Schedule

Bullous Pemphigoid After COVID-19 Vaccination



Bullous Pemphigoid After COVID-19 Vaccination: Correspondence

Summary: This correspondence in Wound Management & Prevention (December 2024) discusses potential bullous pemphigoid (BP) cases following inactivated SARS-CoV-2 vaccination, referencing a report of two Chinese patients with BP history and cerebral infarction. Baseline blood tests were normal, diagnosis confirmed via lab and histologic tests, and genetic factor HLA-DQB1*03:02 was identified. The authors stress the need for more research to establish a clinical link, caution against misinterpreting online reports without full health data, and highlight the role of comorbidities or genetic variations in immune responses, urging exclusion of aggravating factors before attributing BP to vaccination.

Key Highlights:

  • BP diagnosed post-inactivated SARS-CoV-2 vaccination in two cases with cerebral infarction history.
  • Diagnosis confirmed by laboratory and histologic tests; no baseline blood anomalies noted.
  • Genetic factor HLA-DQB1*03:02 identified in affected patients.
  • Call for further studies to confirm vaccine-BP link, considering comorbidities and immune status.
  • Emphasis on genetic variations influencing vaccine responses and need to exclude other factors.

Read full article

Keywords: bullous pemphigoid, COVID-19 vaccination, inactivated SARS-CoV-2, HLA-DQB1, comorbidities

From Pressure to Prevention: Rethinking Ulcer Care in Emergency Settings



From Pressure to Prevention: Rethinking Ulcer Care in Emergency Settings

Summary: This webinar, hosted during #STOPTHEPRESSURE week, examines pressure ulcer prevention in emergency settings, focusing on challenges in Emergency Departments (ED) and pre-hospital care. It highlights barriers such as limited space in ambulances, corridor care, and prolonged trolley use, alongside staff shortages and inadequate training for paramedics on skin checks. Collaborative efforts between North Bristol Trust ED teams and South Western Ambulance Service (SWAST) aim to improve outcomes through better skin assessments, use of repose overlays, trauma mattresses, and dynamic mattresses for high-risk patients. The event features panel discussions on patient dignity, frailty increases, and system-driven changes to reduce harm and transform care culture.

Key Highlights:

  • Challenges in ED and ambulance settings include limited repositioning space, patients on chairs or trolleys for extended periods, and dignity issues during skin checks.
  • Staff recognize that corridor care and ambulance waits deviate from standard care, with paramedics prioritizing clinical assessments over pressure ulcer checks due to minimal training.
  • Collaborative working between ED teams and SWAST enhances skin checks and early pressure ulcer detection.
  • Patient comfort improves with repose overlays on trolleys and trauma mattresses, even for low-risk individuals.
  • High-risk patients benefit from beds with hybrid dynamic or full dynamic mattresses to prevent ulcers.

Read full article

Keywords: pressure ulcers, emergency departments, ambulance services, skin checks, dynamic mattresses

Gene Therapy Emerges as a Potentially New Tool in Wound Healing for …



Gene Therapy Emerges as a Potentially New Tool in Wound Healing for People with Vascular Disease: The LEGenD-1 Trial

Summary: The LEGenD-1 trial, published in Circulation: Cardiovascular Interventions, demonstrates that gene therapy using AMG0001 (a plasmid encoding hepatocyte growth factor) can accelerate wound healing in patients with chronic limb-threatening ischemia (CLTI) and neuroischemic ulcers. This phase II, double-blind, randomized, placebo-controlled study involved 75 participants across 22 U.S. sites, where intramuscular injections were administered along a target artery path. Results showed a significant reduction in median time to healing (84 days vs. 280 days for placebo) and higher complete healing rates at 6 and 12 months. The therapy promotes therapeutic angiogenesis and microvascular perfusion, offering a potential complement to revascularization for patients in a therapeutic gap, with balanced safety across groups.

Key Highlights:

  • AMG0001 gene therapy shortened median healing time to 84 days compared to 280 days for placebo (P=0.007).
  • Complete ulcer healing rates were 63.3% at 6 months and 77.6% at 12 months for AMG0001, versus 38.5% and 46.2% for placebo.
  • The study targeted patients with CLTI and neuroischemic ulcers, focusing on earlier-stage intervention beyond revascularization.
  • Therapy involves intramuscular delivery of hepatocyte growth factor plasmid to promote angiogenesis and improve microcirculation.
  • Adverse events were similar across groups, with no procedure-related influences on outcomes.

Read full article

Keywords: gene therapy, wound healing, diabetic ulcers, CLTI, therapeutic angiogenesis

Skin Substitute Fraud in Arizona: A Wake-Up Call for Wound Care Reimbursement



Skin Substitute Fraud in Arizona: A Wake-Up Call for Wound Care Reimbursement

Summary: In a landmark Medicare fraud case, Arizona’s Alexandra Gehrke and Jeffrey King were sentenced to 15.5 and 14 years in prison, respectively, for billing over $1.2 billion for medically unnecessary amniotic skin substitutes applied to elderly and hospice patients, including those with healed or infected wounds. Operating through Apex Medical and Viking Medical, they ordered oversized grafts (4×6 cm+) for maximum reimbursement, paying kickbacks to untrained sales reps and NPs who ignored medical necessity, leading to $410M forfeiture and $600M+ restitution each. The case exposes systemic vulnerabilities in skin substitute billing for diabetic ulcers and chronic wounds, urging providers to flag red flags like volume-based pay and unverified referrals to protect patients and prevent waste.

Key Highlights:

  • Fraud Scheme: Untrained reps targeted vulnerable patients; grafts applied to infection, healed, or non-responsive wounds; kickbacks exceeded $279M.
  • Financial Scale: $1.2B false claims to Medicare/TRICARE/CHAMPVA; 50%+ from unnecessary grafts for small ulcers.
  • Sentencing: Judge Roslyn Silver called them “criminally greedy”; 29.5 years combined prison, $1.2B restitution.
  • Red Flags for Providers: Unwritten billing reassignments, volume-tied pay, small wounds getting large grafts, dual records.
  • Implications for Diabetic Ulcers: Highlights reimbursement abuse in wound care; calls for ethical billing, training, and oversight to avoid harming patients with neuropathy or poor perfusion.

Read full article

Keywords: skin substitute fraud, diabetic ulcers, Medicare reimbursement, kickbacks, wound care ethics

What is the Key to Preventing Type 2 Diabetes?



What is the Key to Preventing Type 2 Diabetes?

Summary: This article explores the primary strategies for preventing type 2 diabetes (T2D), emphasizing that lifestyle modifications—such as modest weight loss (5-7% body weight), 150 minutes of moderate exercise, and a diet rich in fiber/low in refined carbs—can reduce incidence by up to 58% in high-risk individuals. Drawing from the Diabetes Prevention Program, it highlights prediabetes screening (A1C 5.7-6.4%) and early interventions like metformin for those over 60 or with BMI>35, tying prevention to averting complications like neuropathy and foot ulcers. With T2D affecting 38M Americans, the piece stresses sustainable changes over quick fixes, including sleep, stress management, and regular check-ups, to improve glycemic control and wound healing risks.

Key Highlights:

  • Prediabetes: Affects 98M adults; 5-10% annual conversion to T2D without intervention.
  • Lifestyle Impact: DPP study showed 58% risk reduction with diet/exercise; 31% with metformin.
  • Diet Tips: Focus on whole foods, portion control, limit sugars; Mediterranean diet lowers risk 52%.
  • Exercise: 30 min/day aerobic + strength; reduces insulin resistance and supports neuropathy prevention.
  • Complications Link: Poor control leads to neuropathy/ulcers; prevention via A1C<7% cuts DFU risk 50%.

Read full article

Keywords: type 2 diabetes prevention, prediabetes, lifestyle changes, glycemic control, diabetic complications

Assessment of Non-Healing Wounds in Clinical Practice



Assessment of Non-Healing Wounds in Clinical Practice: Towards a Holistic and Systems-Based Approach

Summary: This article reviews the assessment of non-healing wounds, advocating a holistic, systems-based approach that integrates patient history, comorbidities, and environmental factors with accurate diagnosis to optimize management. Drawing on current guidance, it stresses multidisciplinary evaluation for chronic wounds like diabetic foot ulcers and venous leg ulcers, where delayed healing affects 2-3% of the population and costs billions. Key steps include comprehensive history-taking, vascular/neurological exams, and biopsy for malignancy, emphasizing early referral to prevent progression to infection or amputation, with tools like the TIME framework for structured care.

Key Highlights:

  • Prevalence: Non-healing wounds affect 2-3% of populations, with diabetic ulcers leading to 20% amputation risk if untreated.
  • Holistic Assessment: Include psychosocial factors, nutrition, mobility; use tools like PUSH or Bates-Jensen for objective scoring.
  • Diagnostic Tools: Doppler for vascularity, monofilament for neuropathy; biopsy for suspected cancer or vasculitis.
  • Systems Approach: Multidisciplinary teams (podiatry, vascular, nutrition) improve closure rates by 40%.
  • Implications: Early, comprehensive evaluation reduces costs and enhances QoL; calls for standardized protocols.

Read full article

Keywords: non-healing wounds, holistic assessment, systems-based approach, diabetic ulcers, multidisciplinary care, Aby Mitchell

Next-Generation Wound Care: Guiding the Body to Heal Itself



Next-Generation Wound Care: Guiding the Body to Heal Itself

Summary:** National Taiwan University researchers review multimodal strategies combining physical cues (electricity, light, mechanical forces, pH control) and chemical signals (therapeutic gases like H2S) to mimic natural skin regeneration, accelerating healing in chronic wounds like diabetic ulcers. These gentle stimuli reduce inflammation, kill bacteria, and promote collagen/vascular growth, shifting from passive dressings to active “smart” therapies. Published in Materials Today, the approach promises scarless repair via wearable devices, with potential for personalized, non-invasive treatments.

Key Highlights:

  • Multimodal: Electricity guides migration; light (photothermal) kills bacteria/collagen formation; H2S regulates inflammation/angiogenesis.
  • Chronic Wounds: Targets diabetic/pressure ulcers with persistent infection and poor circulation.
  • Benefits: Faster closure, less scarring; biodegradable materials for sustainability.
  • Future: Training/training for “smart” dressings with controlled cues; human trials needed.
  • Lead: Prof. Zong-Hong Lin: “A revolution from passive to active healing.”

Read full article

Keywords: next gen wound care, multimodal cues, scarless healing, therapeutic gases, diabetic ulcers

Histologics LLC Wound Care Launches Soft K-Bride®, a Revolutionary Wound-Bed Prep …



Histologics LLC Wound Care Launches Soft K-Bride®, a Revolutionary Wound-Bed Prep, Debridement, and Biopsy Device

Summary: Histologics LLC has launched Soft K-Bride®, a versatile device combining wound-bed preparation, debridement, and biopsy capabilities using proprietary Kylon® technology—a hooked brush array that gently removes necrotic tissue, biofilm, and debris while preserving healthy tissue. Designed for chronic wounds like diabetic ulcers and pressure injuries, it features a measured handle for depth assessment, flat head for excision, and concave face for wiping, enabling precise tangential biopsies for lab analysis. Training emphasizes micro-curette friction to prime beds for grafts, promoting antibiotic stewardship and reducing broad-spectrum use, with no scarring or trauma in use.

Key Highlights:

  • Kylon® array: Transforms into frictional micro-curettes under pressure for debridement and biopsy without trauma.
  • Design: Incremented handle measures up to 10cm; flat/concave heads for controlled excision and margins.
  • Applications: Diabetic ulcers, pressure injuries, burns, surgical wounds; entraps tissue for culture/molecular testing.
  • Benefits: Training for clinicians; supports graft integration by priming viable surfaces; no scarring reported.
  • Quote: Dr. Neal Lonky: “Surgical excision into viable tissue assures grafts heal effectively; clears biofilm for better outcomes.”

Read full article

Keywords: Soft K-Bride, Kylon technology, wound debridement, tangential biopsy, chronic wound prep

Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection …



Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates Favorable Effects and Safety

Summary:** In a phase 1b multi-center RCT, topical pravibismane—a broad-spectrum anti-infective targeting biofilm pathogens—was safe and well-tolerated in 53 patients with moderate-severe diabetic foot ulcer infections over 4 weeks as adjunct to standard care. It achieved ~3x greater ulcer size reduction, substantially lower amputation rates, and microbiological clearance of key bacteria vs placebo. The findings warrant further development for resistant infections in DFUs, where biofilms hinder 50% of cases.

Key Highlights:

  • Trial: Double-blind, placebo-controlled; 53 participants; primary: safety; secondary: size reduction, amputations, microbiology.
  • Safety: Well-tolerated across doses; no significant issues.
  • Efficacy: 3x ulcer reduction; lower amputations; effective vs biofilm-forming pathogens.
  • Authors: Benjamin Lipsky, David Armstrong, Kim PJ, Murphy B, McKernan PA, Baker BHJ.
  • Implications: Addresses AMR; potential for faster closure in infected DFUs.

Read full article

Keywords: topical pravibismane, diabetic foot infection, biofilm, amputation rates, phase 1b trial

Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing and …



Observational Study of Venous Leg Ulcer Treated With a Native Collagen-Alginate Dressing and the Impact on Wound-Related Quality of Life

Summary: In an observational single-center study of 60 patients with non-healing venous leg ulcers (VLUs; mean duration 1.5-24 months), a collagen-alginate dressing with standard care (compression, debridement) reduced mean wound area from 17.8 to 11.4 cm² (32% relative reduction, P<0.0001) over 4 weeks, with 8% complete closure. Pain dropped (VAS 3.9 to 1.7, P<0.0001), analgesic use halved, and QoL improved (total score P<0.0001), correlating with wellbeing gains. Clinicians rated it 'very good' (98%), with no serious AEs, positioning it as effective for stalled VLUs.

Key Highlights:

  • Wound area: 32.2% mean reduction; 4/50 complete closures (8%).
  • Pain: VAS decreased 2.2 points; pain-free patients rose from 15% to 49%; analgesics from 61% to 33%.
  • QoL: Total score improved; wellbeing sub-score correlated with area reduction (P=0.0002).
  • Safety: 8 moderate AEs (unlikely related); exudate reduced 43%; periwound improved.
  • Authors: Alisha Oropallo, MD; Amit Rao, MD; Sally Kaplan, RN; Farisha Baksh, BS; Christina Del Pin, MD; Julie Isgro, NP.

Read full article

Keywords: collagen alginate, venous leg ulcer, wound QoL, compression therapy, VLU healing

Total-Contact Casts: Healing Ulcers Fast—with Remarkably Low Reported Thrombosis Risk



Total-Contact Casts: Healing Ulcers Fast—with Remarkably Low Reported Thrombosis Risk

Summary: Total-contact casts (TCCs) remain the gold standard for offloading diabetic foot ulcers in tolerant patients, alongside irremovable devices, but concerns about immobility-related venous thrombosis have limited use. A recent systematic review reports remarkably low DVT rates (~0.7%, 1 in 136 cases) with TCCs, compared to up to 40% in general lower-limb immobilization, attributing protection to frequent recasting and partial mobility. This reinforces TCCs’ role in accelerating ulcer healing while minimizing vascular risks, calling for broader adoption in diabetic wound care.

Key Highlights:

  • TCCs or irremovable casts are top for offloading diabetic foot ulcers in suitable patients.
  • DVT prevalence with TCCs: ~0.7% (1/136 cases), far below 40% in standard immobilization.
  • Factors reducing risk: Regular recasting, partial weight-bearing during therapy.
  • Implications: Addresses thrombosis fears, promoting faster healing without heightened vascular concerns.
  • Authors: Tsai R, Bazikian S, Shin L, Woelfel S, Armstrong DG.

Read full article

Keywords: total contact cast, diabetic ulcer, DVT risk, offloading, thrombosis

Integrated Chinese-Western Medicine for Refractory DFU



Integrated Treatment Utilizing Both Chinese and Western Medicine for Refractory Diabetic Foot Ulcers

Summary: This case report describes a 57-year-old man with a 20-year diabetes history and Wagner grade IV diabetic foot ulcer (DFU) that progressed to near-amputation despite standard Western care. An integrated protocol combining Chinese herbal fumigation (to enhance circulation/debride), acupuncture (for pain/neuropathy), and Western IV antibiotics/sharp debridement led to 90% wound reduction by month 2, granulation by week 8, and complete epithelialization by week 12, with ABI improving from 0.6 to 0.9 and no recurrence at 6 months. The approach highlights TCM’s holistic benefits complementing Western precision for refractory DFUs, suggesting potential for broader use in diabetic wound care.

Key Highlights:

  • Patient: 57M, BMI 25.4, HbA1c 8.9%; 10×8 cm ulcer with exposed bone, foul odor, severe pain (VAS 8).
  • Treatment: Herbal fumigation (Angelica sinensis, etc.) BID 20 min; acupuncture (ST36/SP6); ceftazidime + debridement daily; glycemic control.
  • Progress: Week 4: 40% reduction, granulation start; Month 3: Full closure; pain to VAS 2; no AEs.
  • Mechanisms: TCM improves microcirculation/immunity; Western targets infection; synergy accelerates repair.
  • Implications: Cost-effective for refractory cases; calls for RCTs to validate in diabetic ulcer management.

Read full article

Keywords: integrated medicine, refractory DFU, herbal fumigation, acupuncture, Wagner grade IV

New National Perioperative Guideline for Geriatric Surgical Quality Care is Released



New National Perioperative Guideline for Geriatric Surgical Quality Care is Released

Summary:** The American College of Surgeons and AGS have released a new perioperative guideline for geriatric patients, covering 9 domains including nutrition, UTI prevention, functional decline, and pressure ulcer care. It recommends preoperative assessments, frailty screening, and post-op mobilization to minimize complications like wounds from immobility. For pressure ulcers, it advocates risk screening, repositioning, and specialized surfaces, integrating with infection control for better recovery in surgical elderly.

Key Highlights:

  • Domains: 9 areas from pre-op to discharge; pressure ulcers addressed via Braden screening and preventive protocols.
  • Recommendations: Multidisciplinary teams; nutrition for healing; early mobilization to prevent decubitus.
  • Evidence: Based on 50+ studies; reduces readmissions by 20% with adherence.
  • Implementation: Tools for shared decision-making; focus on post-op wound monitoring.
  • Impact: Improves outcomes for 50%+ of surgical patients over 65.

Read full article

Keywords: geriatric surgery, pressure ulcer guideline, perioperative care, frailty screening, elderly wound management

Spiddal Company Launches “Ground-Breaking” Wound Care Device



Spiddal Company Launches “Ground-Breaking” Wound Care Device

Summary:** FeelTect, a Spiddal-based medtech firm, has launched Tight Alright—a wearable device that monitors and adjusts compression in real-time for wound care, targeting venous ulcers and lymphedema. Using sensors and AI, it ensures optimal pressure to promote healing while preventing complications like tissue damage. With €1.5M investment, the device aims to transform outpatient management, reducing hospital visits and improving adherence in chronic wounds.

Key Highlights:

  • Technology: Wearable sensors track pressure, moisture, and movement; AI app adjusts via alerts or automated inflation.
  • Applications: Venous ulcers, lymphedema, post-surgical swelling; reduces 30% non-compliance in compression therapy.
  • Funding: €1.5M from Enterprise Ireland; CEO: “A game-changer for patient-centered wound care.”
  • Impact: Improves circulation, accelerates closure; trials show 25% faster healing.
  • Launch: Available Q1 2026; partnerships with HSE for rollout.

Read full article

Keywords: compression device, real-time monitoring, venous ulcers, AI wound care, FeelTect

Guideline Adherence, Team Approach to Prevention Impacts Surgical Site Infections



Guideline Adherence, Team Approach to Prevention Impacts Surgical Site Infections

Summary:** This review of 20+ studies demonstrates that strict adherence to SSI prevention guidelines—antibiotic timing, normothermia, and hair removal—combined with multidisciplinary teams (surgeons, nurses, IPs) reduces infection rates by 25-40%. Post-discharge wound care education is crucial, as 50% of SSIs occur after hospital stay; tools like apps for monitoring improve compliance and outcomes in high-risk surgeries like orthopedic or vascular procedures.

Key Highlights:

  • Adherence Impact: 95% compliance lowers SSIs by 30%; gaps in post-op care contribute 60% of cases.
  • Team Benefits: MDT protocols cut re-admissions; nurse-led education boosts patient self-monitoring.
  • Post-Discharge: Digital tools for wound checks; patient guidance on hygiene and signs of infection essential.
  • Evidence: Meta-analysis of 15 RCTs; NNT 8 for guideline bundles.
  • Implications: Standardize education; integrate IPs for waste reduction in wound care.

Read full article

Keywords: SSI prevention, guideline adherence, multidisciplinary team, post-discharge care, surgical wounds

Enzyme Involved in Glucose Metabolism Promotes Wound Healing, Study Finds



Enzyme Involved in Glucose Metabolism Promotes Wound Healing, Study Finds

Summary:** Georgia State University researchers reveal that pyruvate kinase M2 (PKM2)—an enzyme in glucose metabolism—accelerates wound healing when released by neutrophils. In mouse models, PKM2 enhanced keratinocyte migration and proliferation via metabolic reprogramming, reducing inflammation and improving closure in diabetic ulcers. This suggests PKM2 as a therapeutic target or mimic for stalled chronic wounds, potentially via topical delivery to boost repair without antibiotics.

Key Highlights:

  • Mechanism: PKM2 shifts glucose to glycolysis for energy in healing cells; neutrophil release directs repair.
  • Models: Diabetic mice showed 40% faster closure with PKM2; reduced TNF-α and boosted VEGF.
  • Implications: Targets chronic wounds with metabolic defects; potential for PKM2 agonists in dressings.
  • Publication: Nature Communications (2025); DOI: 10.1038/s41467-025-51234-6.
  • Expert: Lead author Dr. Ying Li: “PKM2 could transform how we treat non-healing wounds.”

Read full article

Keywords: PKM2 enzyme, glucose metabolism, neutrophil release, diabetic ulcers, metabolic reprogramming

AI x Medicine: Identifying CTSH Gene in Diabetic Foot Ulcer Using Bioinformatics



AI x Medicine: Identifying CTSH Gene in Diabetic Foot Ulcer Using Bioinformatics and Machine Learning

Summary: This Twitter-highlighted publication from the Journal of Inflammation Research (2024) employs bioinformatics and machine learning to pinpoint CTSH as a critical extracellular matrix (ECM)-related gene in diabetic foot ulcers (DFU), validated in mouse models. Analyzing GEO datasets, the study identified CTSH’s upregulation in DFUs, correlating with inflammation and poor healing. ML models predicted CTSH’s diagnostic value (AUC 0.85), while knockdown in mice enhanced wound closure via reduced fibrosis and improved angiogenesis. This positions CTSH as a biomarker/target for personalized DFU therapies, addressing ECM dysregulation in diabetic wounds.

Key Highlights:

  • Bioinformatics: CTSH upregulated in DFU datasets; enriched in ECM-receptor interaction and PI3K-Akt pathways.
  • ML Prediction: Random forest model AUC 0.85 for DFU classification; CTSH as top feature.
  • Mouse Validation: CTSH knockdown accelerated closure (day 14 vs 21), reduced inflammation (IL-6/TNF-α), enhanced collagen deposition.
  • Clinical Relevance: Potential biomarker for refractory DFUs; therapeutic knockdown to improve healing.
  • Publication: Journal of Inflammation Research (2024); DOI: 10.2147/JIR.S472345.

Read full article

Keywords: CTSH gene, DFU biomarker, bioinformatics, machine learning, ECM regulation

blaSHV Genes in Bacteria Among Diabetic Foot Ulcer Patients from Selected Referral Hospitals in Uganda



blaSHV Genes in Bacteria Among Diabetic Foot Ulcer Patients from Selected Referral Hospitals in Uganda

Summary: This cross-sectional study at 7 Ugandan hospitals analyzed 117 diabetic foot ulcer (DFU) patients, finding 105 (89.7%) positive for bacterial growth, predominantly Gram-negative (E. coli, Klebsiella). ESBL production was 37.1% (39/105), with blaSHV genes in 71.8% of ESBL isolates, driving high resistance to cephalosporins (90%) and amoxicillin (95%). Gram-positives like S. aureus showed MRSA at 20%. The findings underscore the need for routine ESBL screening, antibiotic stewardship, and surveillance in DFU management to curb infection-driven amputations in low-resource settings.

Key Highlights:

  • Demographics: 117 patients (mean age 58 years, 58% male); 105 cultures positive, 70% Gram-negative.
  • ESBL Prevalence: 37.1%; blaSHV (28/39), blaTEM (24/39); multi-drug resistance in 82% ESBL producers.
  • Resistance Patterns: 90% to 3rd-gen cephalosporins; 95% to amoxicillin; carbapenems effective (85%).
  • Site Variation: Higher ESBL in urban hospitals (Kiruddu 50%, Fort Portal 46%); S. aureus in 30%.
  • Implications: Urgent stewardship; molecular surveillance for DFU pathogens to guide therapy and reduce amputations.

Read full article

Keywords: blaSHV genes, ESBL, diabetic foot ulcers, antibiotic resistance, Uganda DFU

Integrated Treatment Utilizing Both Chinese and Western Medicine for …



Integrated Treatment Utilizing Both Chinese and Western Medicine for Refractory Diabetic Foot Ulcers

Summary: This case report details the successful management of a 57-year-old man with a Wagner grade IV diabetic foot ulcer (DFU) that deteriorated despite standard Western care, leading to near-amputation. An integrated approach combining Chinese herbal fumigation (to promote circulation and debride), acupuncture (for pain and microcirculation), and Western antibiotics/debridement resulted in complete wound closure in 3 months, with improved perfusion and no recurrence at 6 months. The therapy highlights synergy between traditional Chinese medicine’s holistic effects and Western precision, offering a model for refractory DFUs in resource-limited settings to enhance healing and preserve limbs.

Key Highlights:

  • Patient profile: 57-year-old male with 20-year diabetes history, Wagner IV DFU (10×8 cm, exposed bone), failed initial antibiotics/debridement.
  • Intervention: Herbal fumigation (Angelica sinensis, etc.) twice daily for 20 min; acupuncture on ST36/SP6; IV antibiotics + daily sharp debridement.
  • Outcomes: Wound reduced 90% by month 2; granulation by week 8; full epithelialization by week 12; ABI improved from 0.6 to 0.9.
  • Safety: No adverse events; pain reduced from VAS 8 to 2; HbA1c stabilized at 7.2%.
  • Implications: TCM-Western integration enhances microcirculation and immunity; calls for RCTs in refractory DFUs.

Read full article

Keywords: integrated medicine, diabetic foot ulcer, Chinese herbal, acupuncture, refractory DFU

2025 Annual Report: Advancing DFU and CLTI Research in Vascular Wound Care



2025 Annual Report: Advancing DFU and CLTI Research in Vascular Wound Care

Summary:** The 2025 annual report from a vascular research group highlights progress in diabetic foot ulcer (DFU) and chronic limb-threatening ischemia (CLTI) management, including trials for endovascular revascularization, EVAR/FEVAR, and amputation prevention. Key studies evaluate outcomes in DFUs under pressure, with pressure ulcer prevention integrated into pressure management. The report emphasizes multidisciplinary approaches to reduce amputation rates and improve healing in high-risk patients, with data from 2024 trials informing 2025 priorities for wound care innovation.

Key Highlights:

  • DFU Focus: Trials on pressure-related ulcers and neuropathy, integrating vascular support for better closure.
  • CLTI: Endovascular vs. bypass for limb salvage; EVAR/FEVAR for aneurysm-related wounds.
  • Pressure Ulcers: Prevention strategies in immobilized patients, linked to DFU comorbidities.
  • Outcomes: Reduced amputations through early intervention; 2024 data shows 20% improvement in healing rates.
  • Future: 2025 trials on biomaterials and telemedicine for remote DFU monitoring.

Read full article

Keywords: DFU research, CLTI, amputation prevention, vascular trials, pressure ulcers

CARE Hospitals Launches Month-Long Diabetes Awareness Initiative



CARE Hospitals Launches Month-Long Diabetes Awareness Initiative – Focus on Preventing Diabetic Foot Complications

Summary:** CARE Hospitals Group has kicked off a November 2025 diabetes awareness campaign targeting foot complications, with free screenings, workshops, and consultations to educate on early detection of ulcers and neuropathy. Affecting 19-34% of diabetics, foot ulcers lead to infections and amputations if unchecked; the initiative promotes self-exams, proper footwear, and glycemic control, led by experts like Dr. P.C. Gupta. Aimed at 422 million global diabetics, it seeks to cut healthcare burdens through community outreach and policy advocacy for better access.

Key Highlights:

  • Campaign: Free foot checks, workshops on hygiene/nutrition; targets urban/rural diabetics.
  • Risks: 19-34% ulcer incidence; 50% recur within 3 years; 85% amputations precede ulcers.
  • Prevention: Daily inspections, offloading, HbA1c <7%; early referral for neuropathy.
  • Expert: Dr. Gupta: “Awareness saves limbs”; 422M global diabetics, 77M in India.
  • Impact: Reduces infections/amputations; partners with NGOs for screening.

Read full article

Keywords: diabetic foot prevention, awareness campaign, free screening, CARE Hospitals, neuropathy management

Application of Deep Breathing Relaxation Techniques to Reduce Pain Intensity ….



Application of Deep Breathing Relaxation Techniques to Reduce Pain Intensity in Patients with Post-Operative Diabetes Mellitus Ulcers

Summary:** This study assesses deep breathing relaxation as a non-pharmacological intervention for pain management in post-operative diabetic foot ulcer (DFU) patients, demonstrating its efficacy in lowering pain intensity and enhancing recovery. Involving DFU patients undergoing debridement or amputation, the technique—simple inhalation/exhalation with abdominal focus—reduced VAS pain scores from 6.5 to 3.2 (p<0.05) after 10-minute sessions twice daily. It promotes relaxation, improves oxygenation, and boosts compliance with wound care, offering an accessible tool for diabetic complications in resource-limited settings.

Key Highlights:

  • DFU Pain: Post-op pain from debridement or surgery exacerbates stress and delays healing in diabetics.
  • Method: Guided deep breathing (4s inhale, 6s exhale) for 10 min BID; simple, no equipment needed.
  • Results: VAS drop 3.3 points; improved sleep and mobility; no side effects.
  • Mechanisms: Lowers cortisol, enhances endorphins, supports glycemic control.
  • Implications: Complements antibiotics/dressings; recommended for nursing protocols in DFU care.

Read full article

Keywords: deep breathing, DFU pain, non-pharmacological, post-operative care, relaxation techniques

Comprehensive Transcriptomic Profiling Reveals Tissue-Specific Molecular Signatures and ….



Comprehensive Transcriptomic Profiling Reveals Tissue-Specific Molecular Signatures and Dysregulated Pathways in Diabetic Foot Ulcers

Summary:** This study performed RNA sequencing on skin, adipose, and muscle tissues from DFU patients and non-ulcerated diabetic controls to uncover tissue-specific molecular drivers of DFU pathogenesis. Differential expression analyses identified 105 overlapping targets across tissues, with hub genes like AKT1 and MMP9 enriched in oxidative stress, inflammation, and bacterial response pathways (e.g., AGE-RAGE, TNF, IL-17). Refractory DFUs showed upregulated pro-inflammatory genes and downregulated repair factors, suggesting personalized therapies targeting fibrosis and angiogenesis for improved healing in diabetic wounds.

Key Highlights:

  • Dataset: Skin/adipose/muscle from 10 DFU patients vs. 10 controls; 105 common DEGs, 10 hubs (AKT1, EGFR, MMP9).
  • Pathways: Enriched in AGE-RAGE (diabetic complications), TNF/IL-17 (inflammation), bacterial invasion; tissue-specific: skin fibrosis, muscle ECM degradation.
  • Refractory signatures: Upregulated IL6, CDKNs; downregulated CCNA2; links to poor granulation and chronicity.
  • Therapeutic targets: AKT1/HSP90AA1 for survival; MMP9/MAPK8 for matrix preservation and inflammation control.
  • Implications: Supports precision medicine for DFUs; future: RT-qPCR validation in larger cohorts.

Read full article

Keywords: transcriptomic profiling, diabetic foot ulcers, tissue-specific genes, inflammatory pathways, refractory wounds

Smart Hybrid Nanomaterials for Chronic Infections



Smart Hybrid Nanomaterials for Chronic Infections: Microbiome-Responsive and Sustainable Therapeutic Strategies

Summary:** This review explores smart hybrid nanomaterials for treating chronic infections in diabetic foot ulcers (DFUs), leveraging microbiome-specific triggers like pH, redox, or enzymes for on-demand drug release. DFUs, affecting 15-25% of diabetics, often involve biofilms and antibiotic resistance, leading to amputations. Nanomaterials—liposomes, dendrimers, metal-organic frameworks—enhance penetration, target bacteria, and minimize side effects, with examples like pH-sensitive liposomes releasing vancomycin in acidic infected sites. Sustainable aspects include biodegradable polymers and green synthesis, promising cost-effective, localized therapies to overcome systemic antibiotic limitations in DFU management.

Key Highlights:

  • DFU Pathogenesis: Neuropathy, ischemia, and hyperglycemia foster biofilms; 50% become infected, with 20% requiring amputation.
  • Nanomaterial Types: Liposomes for encapsulation, dendrimers for branching delivery, MOFs for high loading; responsive to bacterial metabolites.
  • Mechanisms: pH/redox-responsive release in infected microenvironments; photothermal therapy with nanoparticles kills bacteria via heat.
  • Sustainability: Biodegradable carriers reduce environmental impact; green synthesis using plant extracts for eco-friendly production.
  • Challenges/Future: Clinical translation needed; combination with phage or CRISPR for multi-modal DFU therapy.

Read full article

Keywords: nanomaterials, diabetic foot ulcers, microbiome-responsive, biofilm therapy, sustainable nanotech

Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers



Risk Management Is Important to Healthcare Facilities in Order to Prevent Pressure Ulcers

Summary: This article discusses the critical role of risk management in healthcare to mitigate pressure ulcers (bedsores), a common complication in nursing homes and hospitals from prolonged immobility. It highlights prevention programs including regular skin assessments, repositioning schedules, and specialized mattresses to redistribute pressure, alongside staff training and documentation to avoid legal and financial liabilities. By addressing root causes like poor nutrition and incontinence, facilities can reduce incidence, enhance patient outcomes, and comply with regulations, ultimately lowering waste from extended stays and treatments.

Key Highlights:

  • Pressure ulcers form from sustained pressure on bony prominences, leading to tissue damage and infection risks in immobile patients.
  • Prevention strategies: Hourly turning, barrier creams for incontinence, high-protein diets, and Braden Scale assessments for early risk detection.
  • Specialized equipment: Alternating air mattresses or foam overlays reduce shear and friction for high-risk individuals.
  • Legal implications: Proper documentation defends against negligence claims; failure to prevent can result in lawsuits and fines.
  • Overall benefits: Proactive management cuts readmissions, shortens healing time, and improves quality of life for vulnerable patients.

Read full article

Keywords: pressure ulcers, risk management, nursing home care, skin assessment, repositioning schedules

Hospital Safety Climate and Organizational Characteristics Predict HAIs and …



Hospital Safety Climate and Organizational Characteristics Predict HAIs and Occupational Health Outcomes

Summary: This multi-site study reveals that a robust patient safety climate and adherence to standard precautions significantly reduce hospital-acquired infections (HAIs) like MRSA and CAUTI, as well as occupational exposures, explaining 23-43% of variance alongside factors like nurse staffing and Magnet status. Observed adherence is suboptimal at 64.4%, particularly in hand hygiene, highlighting opportunities for infection preventionists (IPs) to use observational tools for cross-cutting surveillance, including pressure ulcer prevention, to enhance situational awareness and integrate care standards for better wound and occupational safety outcomes.

Key Highlights:

  • Safety Climate: Stronger climate boosts adherence to precautions, lowering HAIs (e.g., MRSA, CAUTI) and injuries (needlesticks, mucocutaneous).
  • Adherence Gaps: 64.4% overall; role differences (e.g., nurses higher in hand hygiene); underreporting worsens trends.
  • Organizational Factors: Nurse staffing and professional environments influence outcomes; Magnet hospitals show better safety.
  • Pressure Ulcers: IPs coordinate prevention as part of complex care; surveillance tools aid awareness in wound-related HAIs.
  • Future: AHRQ-funded SIPPS Trial tests simulation for precautions; calls for IP-led interventions.

Read full article

Keywords: hospital safety climate, HAIs, pressure ulcer prevention, standard precautions, infection preventionists

Diabetic Foot Care: New Tech & Preventing Amputations


Diabetic Foot Care: New Tech & Preventing Amputations

Summary: With 1 in 5 diabetics facing foot ulcers and up to 20% leading to amputation (costing >$30,000/case), this article explores innovations like AI for early detection, bioengineered skin substitutes, hyperbaric oxygen therapy (HBOT), phage therapy, and telehealth to improve outcomes and accessibility. Emphasizing prevention through daily inspections, proper footwear, and glycemic control, it highlights tools like Podimetrics’ remote monitoring and community education to enhance adherence, ultimately reducing mobility loss and long-term healthcare burdens.

Key Highlights:

  • Stats: 15% lifetime DFU risk; 25-33% amputation rate; $9B+ annual U.S. cost.
  • AI Detection: Analyzes gait/genetics for risk prediction; Podimetrics uses images/patient data for proactive care.
  • Wound Tech: Stem cells/platelet-rich plasma accelerate healing; bioengineered scaffolds support growth; HBOT boosts perfusion; phage targets resistant bacteria.
  • Telehealth: Remote consults cut amputations (e.g., VA programs); challenges: equity, privacy.
  • Prevention: Foot checks, smoking cessation, BMI control; peer support for adherence.

Read full article

Keywords: diabetic foot care, amputation prevention, AI prediction, phage therapy, telehealth wounds

Atom Insights, Superbug Cure & Healing Advances – Oct 29, 2025



Science News: Atom Insights, Superbug Cure & Healing Advances – Oct 29, 2025

Summary: This roundup spotlights emerging regenerative therapies for chronic wounds, including electrical stimulation to reprogram macrophages for faster diabetic ulcer healing, flatworm stem cell mechanisms for long-distance tissue communication, and a novel antibiotic 100 times more potent against superbugs like MRSA with no resistance development. Building on decades of research, these innovations promise to shift wound care from management to true regrowth, improving outcomes for conditions like arthritis and enhancing healthspan by tackling inflammation and injury at the cellular level.

Key Highlights:

  • Macrophage reprogramming: Targeted electrical stimulation accelerates tissue repair in hard-to-heal diabetic ulcers by boosting immune response.
  • Flatworm regeneration: Insights into stem cell signaling enable distant cellular coordination, potential for organ repair in chronic wounds.
  • Superbug antibiotic: 100x stronger than current drugs, kills MRSA without resistance, addressing biofilm challenges in ulcers.
  • Microbiome focus: Novel compounds from gut flora enhance healing and combat chronic inflammation.
  • Broader impact: Beyond wounds, applications in arthritis and aging, emphasizing preventive regenerative strategies.

Read full article

Keywords: regenerative medicine, diabetic ulcers, superbug therapy, macrophage reprogramming, antibiotic resistance

CAMPs Evidence Compendium 2025: Unifying Cellular, Acellular, and ….



CAMPs Evidence Compendium 2025: Unifying Cellular, Acellular, and Matrix Products for Chronic Wound Care

Summary: This October 2025 compendium from the Journal of Wound Care consolidates evidence on Cellular, Acellular, and Matrix-like Products (CAMPs), including placental allografts and ECM scaffolds, for chronic wounds like DFUs, VLUs, and pressure ulcers. Featuring 40+ authors, it reviews RCTs, case series, and economic models showing 50-98% closure rates, 35-80% amputation reductions, and $170/pt savings, while addressing reimbursement caps and fraud. It advocates MDT integration, fixed-fee models ($400-704/cm²), and registries for standardized coverage, positioning CAMPs as early interventions to enhance granulation and prevent complications.

Key Highlights:

  • Authors: 50+ experts, including William Tettelbach, Martha Kelso, David Armstrong; editorial team led by Shruti Kamath.
  • Evidence: dACM RCT (50% closure vs 35% SOC); FT-DPM (48% vs 27%); carePATCH (77.4-100% PAR); overall 86% closure in series.
  • Reimbursement: Proposes $400/cm² fixed fee for $2B savings; LCD limits (8 apps/16 wks) cause 30% failure; calls for AI oversight.
  • Policy: National Coverage Determination for equity; registries for accountability; targets fraud without access barriers.
  • Outcomes: QALY gains, fewer admissions; mechanisms: granulation promotion, infection control, ECM support.

Read full article

Keywords: CAMPs, placental allografts, chronic wounds, reimbursement policy, wound care evidence

The Skin-Substitute Debate: Balancing Access and Costs in Wound Care



The Skin-Substitute Debate: Balancing Access and Costs in Wound Care

Summary: Medicare’s skin substitute spending for chronic wounds is projected at $15B in 2025, up 50% from 2024, prompting a debate between ACOs alleging fraud/waste and manufacturers warning of access barriers. CMS proposes capping reimbursement at $125/cm² to curb $7.7B first-half spend, but the MASS Coalition argues it ignores root causes like promo and could drive $100B+ in hospital costs. With 25M affected Americans, the piece highlights calls for AI oversight, accreditation, and registries to protect evidence-based therapies like allografts for DFUs and VLUs.

Key Highlights:

  • Spending: $7.7B in H1 2025; total $15B projected, from $1.6B in 2022.
  • ACOs’ View: Wasteful/fraudulent; NAACOS urges CMS action for Medicare sustainability.
  • Industry Response: CMS cuts won’t fix fraud; may increase costs via longer hospital stays.
  • Proposed Fixes: AI for billing, national coverage, provider accreditation, outcomes registries.
  • Impact: Risks patient harm; uniform LCDs needed for equity in wound care access.
  • Read full article

    Keywords: skin substitutes, Medicare reimbursement, wound care policy, wasteful spending, DFU access

    Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial ….



    Lakewood-Amedex Biotherapeutics Announces Peer-Reviewed Publication Demonstrating Potent Antimicrobial Activity of Bisphosphocin® Class Against Resistant Pathogens

    Summary: Lakewood-Amedex Biotherapeutics announces a peer-reviewed publication in Antimicrobial Agents and Chemotherapy detailing Bisphosphocin® Nu-3’s broad-spectrum activity against resistant pathogens, including MRSA, E. coli, Pseudomonas, Klebsiella, and Acinetobacter. The study shows Nu-3 kills bacteria in minutes via membrane destabilization, with no resistance in 21-passage tests, positioning it as a topical gel for mildly infected diabetic foot ulcers (iDFUs). With 13 million U.S. iDFU cases yearly and 50% infection rate, Nu-3 addresses systemic antibiotic failures in poor-perfusion tissues, advancing to Phase 2 trials for chronic wound care.

    Key Highlights:

  • Publication: “In Vitro and In Vivo Characterization of Bisphosphocin® Nu-3 – A Novel Broad Spectrum Antimicrobial Compound with High Potency Against Resistant Pathogens” (Oct 22, 2025).
  • Efficacy: Rapid cidal action at topical concentrations; low resistance propensity due to unique mechanism.
  • iDFU Focus: Targets 50% infected ulcers; overcomes poor penetration of systemic antibiotics.
  • Development: Gel formulation for Phase 2; potential for UTI/pulmonary infections.
  • Impact: Addresses 5M global AMR deaths; CEO Kelvin Cooper: “A game-changer for wound care.”
  • Read full article

    Keywords: Bisphosphocin Nu-3, antimicrobial, diabetic foot ulcers, AMR, membrane destabilization

    Wound Bed Preparation with Topical Desiccating Agent



    Early Clinical Experience with a Topical Desiccating Agent for Wound Bed Preparation in Diabetic Foot Ulcers

    Summary: This retrospective case series evaluated a novel topical desiccating agent (TDA) under compassionate use for wound bed preparation in 67 patients with chronic diabetic foot ulcers (DFUs) from 2020-2023. TDA facilitated debridement and granulation, achieving granulation in 88.1% (mean 44.3 days) and complete re-epithelialization in 85.1%, with no adverse events. The agent offers a safe, non-invasive option for high-risk cases, supporting further prospective validation for DFU protocols.

    Key Highlights:

    • Cohort: 67 adults with stalled DFUs; ethics-approved compassionate use.
    • Granulation: 88.1% success; mean time 44.3 days to ready for grafting/closure.
    • Healing: 85.1% full re-epithelialization; rapid progression post-TDA.
    • Safety: No AEs; well-tolerated in diabetics.
    • Implications: Chemical debridement adjunct; calls for RCTs.

    Read full article

    Keywords: topical desiccating agent, diabetic foot ulcers, wound bed preparation, granulation, chemical debridement

    Epidermolysis Bullosa Argentina: Butterfly Skin & Garrahan Hospital Care



    Epidermolysis Bullosa Argentina: Butterfly Skin & Garrahan Hospital Care

    Summary: In Argentina, epidermolysis bullosa (EB) affects ~1,200 people with “butterfly skin” that blisters from minor friction, requiring lifelong wound care to prevent infections. Garrahan Hospital leads with multidisciplinary teams for diagnosis, nutrition, pain management, and mental health, while CEDIGEA advances genetic sequencing for mutation-specific therapies. Challenges include malnutrition from esophageal strictures, chronic pain, and social isolation, but hope lies in gene therapy, protein replacement, stem cells, and bioengineered skins. Support groups like Alas de Mariposa advocate for funding and awareness to shift from symptom relief to cures.

    Key Highlights:

  • EB spectrum: Lethal infancy forms to adult chronic cases; skin adhesion gene mutations cause fragility beyond skin to organs.
  • Diagnosis: Genomic sequencing at CEDIGEA pinpoints mutations for tailored care and therapy targeting.
  • Care at Garrahan: Integrates wound prevention, nutrition, pain relief, and psych support; model for regional EB management.
  • Emerging therapies: Gene therapy restores proteins; stem cells regenerate skin; advanced dressings/bioengineered substitutes reduce infections.
  • Advocacy: Alas de Mariposa provides resources; calls for donations, awareness, and policy for rare disease access.
  • Read full article

    Keywords: epidermolysis bullosa, butterfly skin, Garrahan Hospital, gene therapy, EB care

    Technion Scientists Create Mollusk-Inspired Adhesive That Seals Wounds in Seconds



    Technion Scientists Create Mollusk-Inspired Adhesive That Seals Wounds in Seconds

    Summary: Researchers at Israel’s Technion have engineered a mussel-inspired bioadhesive that bonds tissues in seconds, even underwater, revolutionizing wound closure for chronic and surgical sites. Mimicking mussel foot proteins with catechol groups for wet adhesion and oxidized crosslinking, the gel forms a strong, flexible seal without sutures, promoting hemostasis and preventing infection. Tested on rat skin and liver models, it outperforms commercial glues in bond strength and biocompatibility, offering a non-invasive solution for diabetic ulcers, burns, and trauma wounds where traditional methods fail.

    Key Highlights:

    • Mechanism: Catechol oxidation creates covalent bonds for rapid curing (5-10 seconds) in moist environments.
    • Materials: Biodegradable polymers with mussel-mimicking peptides; tunable viscosity for injection or spraying.
    • Efficacy: 10x stronger adhesion than fibrin glues; full hemostasis in liver incisions; no inflammation in 7-day implants.
    • Applications: Ideal for DFUs, internal bleeding, and minimally invasive surgery; scalable for clinical use.
    • Future: Human trials planned; potential to reduce scarring and infection in chronic wound care.

    Read full article

    Keywords: mussel-inspired adhesive, instant wound sealant, catechol chemistry, biocompatible glue, Technion innovation

    Kenya’s Wound Care Crisis and the Urgent Need for Early Intervention to Prevent Amputations



    Kenya’s Wound Care Crisis and the Urgent Need for Early Intervention to Prevent Amputations

    Summary: Kenya grapples with a mounting wound care crisis, where 15% of adults suffer injuries yearly, leading to untreated chronic conditions, infections, and preventable amputations, particularly in rural areas with 13% wound prevalence. Diabetes amplifies risks, with 22% of wounds developing secondary infections, as seen in cases like Kennedy Chesi Amunavi’s near-amputation from a neglected diabetic ulcer. Experts like Dr. Shilpa Mulki and Dr. Chris Kibiwott advocate for decentralized services, clinician training in diabetic foot management, compression therapy, and biotherapy, alongside awareness campaigns for early screening to save limbs and reduce healthcare burdens.

    Key Highlights:

    • Stats: 15% annual adult injuries; 4% from road crashes, 10.9% unintentional; rural 13% wound rate; 22% secondary infections.
    • Case: Amunavi’s diabetic boil worsened by herbs, nearly requiring amputation, saved via grafting after delays.
    • Gaps: No public hospital wound programs; 46% NCD specialists; rural shortages in nutrition/lab support.
    • Recommendations: Daily foot checks, compression, biotherapy; train generalists; integrate podiatrists/nutritionists.
    • Impact: Early care prevents amputations, preserves livelihoods; calls for county/MoH prioritization.

    Read full article

    Keywords: wound care crisis, diabetic amputations, early intervention, rural wound care, compression therapy

    Thane Fisherman’s Hand Saved from Amputation After Rare Eel Fish Bite in Uttan



    Thane Fisherman’s Hand Saved from Amputation After Rare Eel Fish Bite in Uttan

    Summary: In a dramatic case at Wockhardt Hospitals, Mira Road, a 42-year-old fisherman, Sandip Bhoin, was rescued from limb-threatening infection after a rare double bite from an eel during a fishing trip at Uttan Beach. Arriving 17 hours later with a grossly swollen, pale hand lacking circulation and sensation, he was diagnosed with acute compartment syndrome. Led by Dr. Sushil Nehete, the surgical team performed an emergency fasciotomy to release pressure, restoring blood flow instantly. Post-op, ICU monitoring prevented kidney failure from metabolic waste, and he’s now on track for full recovery with skin grafting and physiotherapy, underscoring the critical role of prompt wound intervention in traumatic marine injuries.

    Key Highlights:

    • Incident: Eel bite caused deep lacerations and heavy bleeding; initial pressure bandage by peers delayed but helped temporarily.
    • Symptoms on arrival: Excruciating pain, swelling, pallor, absent sensation—hallmarks of compartment syndrome obstructing blood flow.
    • Surgery: Fasciotomy released forearm/carpal tunnel pressure; immediate circulation return with rapid sensation/movement improvement.
    • Post-op: ICU averted renal complications; ongoing wound care, grafting, and physio for hand function restoration.
    • Outcome: Hand saved from amputation; full recovery expected in months, emphasizing early referral for trauma wounds.

    Read full article

    Keywords: traumatic wound, compartment syndrome, fasciotomy, marine injury, wound infection

    Hypoxia-Induced Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells …

    Hypoxia-Induced Extracellular Vesicles Derived from Human Umbilical Cord Mesenchymal Stem Cells Regulate Macrophage Polarization and Enhance Angiogenesis to Promote Diabetic Wound Healing

    Summary: Researchers engineered extracellular vesicles (EVs) from human umbilical cord MSCs under hypoxia and showed that these EVs boost fibroblast and endothelial function, activate HIF-1α–VEGFA signaling, promote M2 macrophage polarization, reduce ROS, and accelerate healing in a diabetic wound model.

    Key Highlights:

    • Hypoxia-induced EVs (hy-EVs) improved human skin fibroblast activity and endothelial proliferation/migration versus normoxic EVs.
    • Evidence of angiogenesis via increased HIF-1α, VEGFA, and CD31 expression; aligns with enhanced neovascularization in vivo.
    • Immunomodulation: hy-EVs shifted macrophages from M1 (CD86) to M2 (CD206), dampening inflammatory responses at the wound site.
    • Reduced oxidative stress by inhibiting ROS in fibroblasts and endothelial cells.
    • In diabetic wound models, hy-EVs increased collagen deposition, angiogenesis, and overall healing metrics.
    • Authors propose hy-EV cargo (miRNAs/proteins) as a basis for next-gen EV therapeutics for chronic diabetic wounds.

    Read full article

    Keywords: extracellular vesicles, HUCMSC, hypoxia, HIF-1α, angiogenesis, macrophage polarization, reactive oxygen species, diabetic wound healing, Yongfeng Su, Junda Lu, Feiyuan Liang, Jianwen Cheng

    The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke

    The impact of PANoptosis-related genes on immune profiles and subtype classification in ischemic stroke

    Summary: This open-access computational study profiles PANoptosis-related genes (integrating pyroptosis, apoptosis, and necroptosis) in ischemic stroke blood datasets to define diagnostic gene signatures and immune-infiltration subtypes. While not a wound-care trial, the work offers mechanistic insights into inflammatory cell-death pathways that may inform future translational research across ischemia-driven tissue injury and chronic wound inflammation.

    Key Highlights:

    • Analyzed GEO datasets (e.g., GSE58294) to identify differentially expressed PANoptosis-related genes and build diagnostic models (ROC performance reported).
    • Constructed interaction networks (genes–miRNAs–TFs–drugs) and a nomogram to visualize diagnostic potential.
    • Single-cell re-analysis (GSE174574) mapped candidate genes to immune-cell subpopulations relevant to post-ischemic inflammation.
    • Unsupervised clustering defined two immune subtypes with distinct infiltration patterns and functional pathways.
    • Authors suggest these signatures could guide early diagnosis and targeted therapies in ischemic stroke; pathways overlap with inflammation and cell-death mechanisms studied in chronic wounds.

    Read full article

    Keywords: PANoptosis, pyroptosis, apoptosis, necroptosis, ischemic stroke, bioinformatics, immune infiltration, biomarkers, Xinrui Cai, Yu Ren, Qin Yang

    Molnlycke Health Care Expands Wound Care Manufacturing Facility



    Molnlycke Health Care Expands Wound Care Manufacturing Facility

    Summary: Molnlycke Health Care is investing $135 million to expand its Brunswick, Maine facility, increasing U.S. wound care production capacity with completion targeted for late 2026 or early 2027. The upgrade features advanced U.S.-sourced machinery, renewable energy (wind/solar), and streamlined logistics for sustainability. Over five years, it will create ~10% more jobs (local contractors/suppliers) and faster delivery of products like advanced dressings for chronic wounds, pressure ulcers, and surgical sites. CEO Zlatko Rihter emphasizes resilience and patient access, while GM Chris Biddle highlights community partnerships.

    Key Highlights:

    • Investment scope: $135M for expansion; boosts production of wound care solutions amid rising demand.
    • Sustainability: Integrates wind/solar power; reduces carbon footprint through efficient logistics.
    • Job creation: 10% workforce growth in Maine; engages local economy with suppliers and contractors.
    • Product impact: Enhances supply of dressings for chronic wounds, supporting faster, smarter care.
    • Quotes: Rihter: “A bold step… to deliver high-quality solutions sustainably.” Biddle: “A win for Molnlycke, community, and patients.”

    Read full article

    Keywords: Molnlycke expansion, wound care manufacturing, advanced dressings, sustainable production, chronic wound supply

    From Webs to Wound Healing: ASU Scientists Harness Silk for Medical Innovation



    From Webs to Wound Healing: ASU Scientists Harness Silk for Medical Innovation

    Summary: Arizona State University researchers, led by Professors Jeff Yarger and Kaushal Rege, are pioneering silk proteins from silkworms and spiders for advanced wound healing, as detailed in ACS Biomaterials Science & Engineering. Their laser-activated sealants (LASEs) embed gold nanorods or indocyanine green in silk fibroin matrices, enabling near-infrared laser-triggered heating to seal wounds in seconds—stronger than sutures while minimizing trauma. Versatile forms (fibers, hydrogels, sponges) loaded with antibiotics like vancomycin promote sustained release, biocompatibility, and biodegradation, targeting chronic wounds such as diabetic foot ulcers and pressure sores by enhancing tissue repair and infection prevention.

    Key Highlights:

    • LASEs close wounds instantly via photothermal activation, outperforming sutures in strength and reducing scarring/infection.
    • Silkworm silk fibroin serves as biocompatible matrix; spider egg-case silk explored for tendon-like scaffolds due to superior toughness.
    • Drug delivery: Sustained vancomycin release combats biofilms in chronic wounds; preclinical models confirm efficacy.
    • Versatility: Processable into 3D scaffolds for tissue engineering, personalized dressings with growth factors.
    • Future: Recombinant spider silk production to scale up; applications in DFUs, burns, and surgical sites for faster, safer healing.

    Read full article

    Keywords: spider silk, silk fibroin, laser-activated sealant, chronic wound healing, biodegradable scaffold

    Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb



    Prevention of Infection in Peripheral Arterial Reconstruction of the Lower Limb

    Summary: This Cochrane review synthesizes evidence from 40 RCTs and quasi-RCTs involving 7970 participants on pharmacological and non-pharmacological interventions to prevent infections after lower limb peripheral arterial reconstruction. Prophylactic antibiotics likely reduce surgical site infections (SSIs) and graft infections (low-certainty evidence), but no clear differences exist between short- vs. long-duration regimens or antibiotic types (very low-certainty). Closed incision negative pressure therapy (ciNPWT) may lower SSI and graft infection risks compared to standard closure (very low-certainty), while other methods like dressings or sutures show little benefit. The review highlights the need for standardized trials to guide wound care protocols in vascular surgery, where infections complicate healing and increase amputation risks.

    Key Highlights:

    • Antibiotics vs. none: Reduced SSIs (RR 0.20, 95% CI 0.11-0.34; NNT 9) and graft infections (RR 0.19, 95% CI 0.06-0.63; low-certainty).
    • Short vs. long antibiotics: No difference in SSIs (RR 0.75, 95% CI 0.40-1.40) or graft infections (very low-certainty).
    • ciNPWT vs. standard: Possible reduction in SSIs (RR 0.49, 95% CI 0.27-0.86) and graft infections (RR 0.55, 95% CI 0.19-1.59; very low-certainty).
    • No effects on mortality, re-intervention, or amputation across comparisons (very low- to low-certainty evidence).
    • Implications: Suggest antibiotics for prevention; ciNPWT promising for high-risk surgical wounds; more research needed for dressings and techniques.

    Read full article

    Keywords: peripheral arterial reconstruction, surgical site infection, prophylactic antibiotics, closed incision NPWT, vascular wound care

    The Trump Administration Must Protect Patient Access to Advanced Wound Care



    The Trump Administration Must Protect Patient Access to Advanced Wound Care

    Summary: This opinion piece by Martha Kelso and Rajendra S. Gogia criticizes the Trump administration’s proposed CMS rulemaking to slash reimbursement for advanced wound care therapies, arguing it threatens millions with chronic wounds by ignoring their evidence-based benefits in reducing infections, amputations, and costs. Affecting 25 million Americans (including 6.5 million at any time), these treatments—like bio-engineered substitutes and cellular products—shorten recovery and prevent complications, yet face arbitrary cuts amid fraud concerns. The authors call for smarter reforms: AI-aided billing, accreditation, national coverage determinations, and outcomes registries to balance costs with innovation, noting Trump’s own venous insufficiency as a personal stake in preserving access.

    Key Highlights:

    • Chronic wounds cost billions; advanced care saves money by avoiding hospitalizations/amputations, but proposed cuts risk exacerbating this.
    • Misconceptions: Treatments aren’t wasteful; fraud should be tackled with AI verification, not blanket reductions punishing patients.
    • Policy fixes: National Coverage Determination for uniform access; AI for medical necessity docs; provider accreditation; national registries for accountability.
    • Patient impact: 15% of Medicare beneficiaries affected; delays in care lead to pain, disability, and higher long-term expenses.
    • Personal note: Trump’s venous insufficiency highlights need; urges reversal to protect vulnerable populations.

    Read full article

    Keywords: advanced wound care, CMS reimbursement, chronic wounds, cellular products, wound care policy

    BioLab Holdings Inc. Announces Multiple Clinical Trials to Advance Chronic Wound Care



    BioLab Holdings Inc. Announces Multiple Clinical Trials to Advance Chronic Wound Care

    Full Press Release:

    Phoenix, AZ, October 22, 2025 – BioLab Holdings, Inc., a Phoenix-based medical manufacturer specializing in wound care solutions, announced the ongoing development of several clinical trials to demonstrate the efficacy and safety of its Cellular, Acellular, and Matrix-like Products (CAMPs) in covering and protecting non-healing wounds, including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs). The trials are in response to mandates from the MAC region for robust data to support product efficacy for inclusion in the upcoming Local Coverage Determination (LCD), effective January 1, 2026, for DFUs and VLUs.

    The trials include:

    1. BIOCAMP Trial: A multicenter, prospective, randomized controlled study assessing human placental membrane products combined with standard of care (SOC) versus SOC alone for non-healing DFUs and VLUs. Preliminary data will be presented at the TRES conference on October 30, 2025.

    2. CAMP RWE Trial: A multicenter hybrid platform study comparing tri-layer and single-layer amnion grafts to a matched retrospective control cohort for hard-to-heal DFUs and VLUs. The study will be submitted for publication with Dr. Windy Cole’s assistance.

    3. Retrospective Study: A real-world data collection trial evaluating human amniotic membrane(s) on DFUs, VLUs, pressure ulcers, and post-operative wounds, corroborated by randomized controlled trials.

    4. Meta Analyses & Mega Meta Analysis: BioLab is supporting meta-analyses by Serena Group, including a mega-meta-analysis, to demonstrate similar healing rates across membrane products regardless of brand.

    5. LCD Timeline: The proposed LCD for DFUs and VLUs is effective January 1, 2026, with other wound types requiring standard care prior to use.

    “These trials represent a significant step forward in providing the clinical evidence needed to ensure that our innovative wound care solutions are accessible to patients who need them most,” said BioLab CEO [Name not specified]. “We are committed to advancing the science of chronic wound management and improving outcomes for patients with DFUs and VLUs.”

    About BioLab Holdings, Inc.

    BioLab Holdings, Inc. is a leading manufacturer of advanced wound care products, specializing in human amniotic membrane allografts such as Membrane Wrap Lite™, Tri-Membrane Wrap™, Membrane Wrap™, and Membrane Wrap-Hydro™. These products are designed to support the healing of chronic and non-healing wounds, including DFUs, VLUs, pressure ulcers, and post-operative wounds.

    For more information, visit www.biolabholdings.com.

    Contact: [Contact info not specified]

    Key Highlights:

    • BIOCAMP Trial: Prospective RCT for placental membranes in DFUs/VLUs; preliminary data at TRES October 30, 2025.
    • CAMP RWE Trial: Hybrid study comparing graft layers to controls; submission for publication with Dr. Windy Cole.
    • Retrospective Study: Real-world data on amniotic membranes for multiple wound types, backed by RCTs.
    • Meta-Analyses: Supported by Serena Group to show consistent healing across products for LCD inclusion.
    • LCD Impact: Effective January 1, 2026 for DFUs/VLUs; aims to ensure coverage for BioLab’s allografts.

    Read full article

    Keywords: BioLab Holdings, amniotic membrane, diabetic foot ulcers, venous leg ulcers, LCD coverage

    Artacent Amniotic Tissue for Treatment of Chronic Lower Extremity Diabetic Ulcers



    Clinical Trial: Artacent Amniotic Tissue for Treatment of Chronic Lower Extremity Diabetic Ulcers

    Summary: Sponsored by Tides Medical, this completed interventional Phase 2 trial (NCT07219004, started March 3, 2023) investigates the efficacy of Artacent—a tri-layered dehydrated human amnion/chorion/amnion composite graft—as a treatment for chronic lower extremity diabetic ulcers persisting despite standard care. Enrolling patients with non-healing wounds, the study assesses whether the amniotic tissue promotes closure over 12 weeks, addressing the high burden of diabetic ulcers that affect millions and often lead to amputations. While specific outcomes remain pending publication, the trial underscores amniotic products’ potential in regenerative wound healing by providing a structural matrix for tissue repair and reducing inflammation.

    Key Highlights:

    • Trial design: Interventional, single-group assignment; focuses on 12-week healing in chronic diabetic lower extremity ulcers.
    • Product: Artacent tri-layered graft supports cellular migration and vascularization for stalled wounds.
    • Relevance: Targets non-healing ulcers post-standard care, common in diabetics with vascular/neurological complications.
    • Sponsor: Tides Medical; status: Completed (recruitment finished); no interim efficacy/safety data released yet.
    • Implications: Builds evidence for amniotic membranes in DFU management, potentially improving closure rates and limb salvage.

    Read full article

    Keywords: Artacent, amniotic tissue, diabetic ulcers, phase 2 trial, regenerative graft

    Nagaland University Researchers Find Plant Compound to Treat Diabetic Wound Foot Ulcers



    Nagaland University Researchers Find Plant Compound to Treat Diabetic Wound Foot Ulcers

    Summary: Researchers at Nagaland University have identified sinapic acid, a naturally occurring antioxidant from edible plants, as a powerful therapeutic for accelerating wound healing in diabetic patients, particularly foot ulcers. Published in Nature Scientific Reports, the study demonstrates that oral administration of sinapic acid activates the SIRT1 pathway to promote tissue repair, angiogenesis, and inflammation control in preclinical models. Notably, a lower dose (20 mg/kg) proved more effective than higher doses (40 mg/kg), exhibiting an inverted dose-response curve. This discovery offers a safe, natural, and affordable alternative to synthetic drugs, potentially reducing amputation risks and improving accessibility in resource-limited settings, with pilot clinical trials planned next.

    Key Highlights:

    • Sinapic acid targets diabetic foot ulcers by addressing neuropathy, poor circulation, infections, and oxidative stress through SIRT1 activation.
    • Preclinical results: Oral low-dose sinapic acid enhanced metabolic health, wound closure, and reduced side effects compared to higher doses.
    • Global impact: Diabetes affects millions; delayed healing leads to ulcers and amputations—sinapic acid provides a non-invasive oral solution.
    • Lead researcher: Prof. Pranav Kumar Prabhakar, Head of Biotechnology at Nagaland University, highlights limited efficacy of existing drugs.
    • Future steps: Pilot trials to validate in humans, focusing on rural accessibility and patentable formulations.

    Read full article

    Keywords: sinapic acid, diabetic foot ulcers, SIRT1 activation, oral wound therapy, Nagaland University

    Tips for Scalp Dressings: Securing Head Wounds Effectively



    Tips for Scalp Dressings: Securing Head Wounds Effectively

    Summary: This practical guide from Wounds Africa tackles the unique challenges of dressing scalp wounds on hairy heads, where traditional bandages often slip or cause discomfort. Focusing on malignant wounds (e.g., basal/squamous cell carcinomas), actinic keratoses, burns, and trauma, it outlines eight alternative methods to ensure secure, comfortable coverage while preserving patient vanity and mobility. Techniques range from simple hair clips to advanced turban bandaging, emphasizing soft, non-irritating options like chemotherapy caps. Ideal for chronic or post-surgical care, these tips promote healing by maintaining consistent pressure relief and infection prevention without invasive fixation.

    Key Highlights:

    • Common challenges: Dressings slip on hair, causing pain or exposure; solutions prioritize non-adherent, customizable methods for daily changes.
    • Hair clips method: Secure bandages with clips to avoid tape on hair; combine with underlying tape for stability, removing clips when lying down to prevent marks.
    • Hair tying technique: Use Steri-Strips to tie hair over small dressings for easy, painless removal; effective for minor abrasions or grafts.
    • Tie-over bolster: Reusable sutures anchor bolsters over grafts, ideal for larger scalp defects post-surgery.
    • Net stocking: Soft tubular netting holds multiple dressings; choose finer mesh for comfort on sensitive scalps.
    • Turban bandaging: Preferred long-term method; wrap gauze/tubigrip around head for secure fit—practice recommended for even pressure.
    • Soft coverings: Beanies or chemotherapy caps conceal and secure dressings, boosting patient confidence during healing.
    • Visual aids: Includes illustrations and video links (YouTube/Vimeo) demonstrating each technique for hands-on learning.

    Read full article

    Keywords: scalp dressings, head bandages, turban technique, hair clips, post-surgical scalp wounds

    Essity’s Cutimed launches its first brand campaign

    Essity and Publicis London Reimagine Healing with “Imagine a World” Campaign

    Summary: Essity’s wound-care brand Cutimed launches “Imagine a World,” a new campaign by Publicis London aimed at shifting public perception of chronic wound care. Creative assets spotlight advanced technologies across the Cutimed portfolio and reinforce the message that every wound deserves the right to heal.

    Key Highlights:

    • Brand campaign centered on chronic wound-healing possibilities.
    • Creative includes a master brand film and shorter social formats.
    • Highlights innovations across Cutimed dressings.
    • Supports broader awareness efforts around chronic wounds.

    Read full article

    Keywords: Essity, Cutimed, Publicis London, brand campaign

    Real-world outcomes of a placenta-based tissue product versus standard …

    Real-world outcomes of a placenta-based tissue product versus standard of care for lower extremity diabetic ulcers: a Medicare cohort study

    Summary: This Journal of Wound Care study analyzes Medicare data to compare a placenta-based tissue product with standard care in lower-extremity diabetic ulcers. The product cohort demonstrated favorable healing outcomes in routine practice settings, adding real-world evidence to existing clinical data.

    Key Highlights:

    • Large Medicare dataset; comparative effectiveness design.
    • Placenta-based tissue product associated with improved healing endpoints vs SOC.
    • Supports reimbursement and protocol decisions in outpatient wound centers.
    • Authors call for prospective trials to validate observational signals.

    Read full article

    Keywords: placenta-based tissue product, real-world evidence, Journal of Wound Care, Tettelbach, Tucker

    Activated PRP Plus Angioplasty Enhances Healing in Diabetic Foot Ulcers

    Activated PRP Plus Angioplasty Enhances Healing in Diabetic Foot Ulcers, suggests study

    Summary: Reporting on new evidence from the World Journal of Diabetes, this piece highlights improved DFU healing when vascular intervention (angioplasty) is paired with activated PRP. The dual strategy targets ischemia and tissue regeneration, though authors call for larger randomized trials to standardize PRP protocols.

    Key Highlights:

    • Combination therapy: revascularization + biologic (activated PRP).
    • Enhanced wound-closure metrics compared to single-modality care.
    • Clinical rationale: restore perfusion and stimulate local tissue repair.
    • Next steps: standardize PRP activation, dosing, frequency in RCTs.

    Read full article

    Keywords: PRP, angioplasty, diabetic foot ulcer, World Journal of Diabetes, Huang

    Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates ….

    Phase 1b Data for Topical Pravibismane in Diabetic Foot Ulcer Infection Demonstrates Favorable Effects and Safety

    Summary: Dermatology Times reports Phase 1b results for topical pravibismane used adjunctively in moderate to severe infected diabetic foot ulcers. The therapy was well-tolerated and associated with favorable healing signals alongside standard care, with the source article published in the International Wound Journal.

    Key Highlights:

    • Adjunct topical pravibismane vs placebo in infected DFUs.
    • Safety and tolerability demonstrated across tested doses.
    • Signals toward greater ulcer-size reduction and fewer ulcer-related amputations.
    • Larger, confirmatory trials are warranted.

    Read full article

    Keywords: pravibismane, diabetic foot ulcer, International Wound Journal, Lipsky

    Effects of Oral Cholecalciferol on Chronic Wound Healing in Patients with Vitamin D Insufficiency

    Effects of Oral Cholecalciferol on Chronic Wound Healing in Patients with Vitamin D Insufficiency or Deficiency

    Summary: This peer-reviewed study evaluates whether correcting vitamin D insufficiency with oral cholecalciferol accelerates healing of chronic wounds. Participants receiving vitamin D plus conventional wound care showed faster reductions in wound area/depth and shorter time to healing versus conventional care alone, supporting the integration of deficiency screening and supplementation into routine protocols.

    Key Highlights:

    • Adults with chronic wounds and serum 25(OH)D < 30 ng/mL received short-term, high-dose cholecalciferol.
    • Improved wound-area and depth reduction rates; shorter time-to-healing compared with controls.
    • Findings align with holistic frameworks (e.g., TIME) where systemic factors impact local healing.
    • Authors note need for larger trials to standardize dosing and confirm outcomes.

    Read full article

    Keywords: vitamin D, cholecalciferol, chronic wounds, 25(OH)D, JMDH, Zhao